Anexa nr. 7
la Documentația standard nr.____
din "___" _____ 20__

CERERE DE PARTICIPARE

Către: **IMSP Spitalul Clinic Republican „Timofei Moșneaga",**
(mun.Chișinău, str.N.Testemițanu 29)

Stimaţi domni,

Ca urmare a anunțului de participare apărut în Buletinul achizițiilor publice nr. 100 din 23.12.2025 și/sau Jurnalul Oficial al Uniunii Europene, privind **Achiziționarea Materiale de control extern al calității investigațiilor de laborator pentru anul 2026**, noi **Medist Grup SRL** (denumirea/numele ofertantului/candidatului), am luat cunoștință de condițiile și de cerințele expuse în documentația de atribuire și exprimăm prin prezenta interesul de a participa, în calitate de ofertant/candidat, neavînd obiecții la documentația de atribuire.

Data completării 03.02.2026

Cu stimă,

Ofertant/candidat

Gabriela-Cristina Anghel

(semnătura autorizată)

Digitally signed by Anghel Gabriela-Cristina
Date: 2026.02.03 13:12:05 EET
Reason: MoldSign Signature
Location: Moldova
MOLDOVA EUROPEANĂ

ORDIN DE PLATA **Nr.** 157 DATA EMITERII 03 februarie 2026 TIP DOC : 1

PLATITI: 877-43 LEI opt sute sapte zeci si sapte lei .43 bani

PLATITOR (R) SOCIETATEA CU RASPUNDERE LIMITATA MEDIST GRUP

CODUL IBAN: MD59EX0000002251874012MD

COD FISCAL: 1018600004516

PRESTATORUL PLATITOR: B.C. "EXIMBANK" S.A. SUCURSALA NR.20 CHISINAU

BENEFICIAR (R) I.M.S.P. S.C.R. TIMOFEI MOSNEAGA

CODUL IBAN: MD57MO2251ASV96476607100

COD FISCAL: 1003600150783

PRESTATORUL BENEFICIAR: OTP BANK S.A., CENTRALA

DESTINATIA PLATII

Plata pt garantia pentru oferta in cuantum de 1 procente, LP nr. 21553095 din 20.01.2026

TIPUL TRANSFERULUI NORMAL/URGENT

N

L.S.

COD TRANZACTIE: 001

DATA PRIMIRII: 03 februarie 2026

DATA EXECUTARII: 03 februarie 2026 10:11:56

SEMNATURA BANCII: EF4EE750FD3FA5AB7C395D7250BD80B0

SEMNATURA BANCII

SEMNATURILE EMITENTULUI

GABRIELA-CRISTINA ANGHEL
MCqd
+T8QAcUEusM3GkGDBV88TW3inSlYETLO1+I=
GABRIELA-CRISTINA ANGHEL
MCqd
+T8QAcUEusM3GkGDBV88TW3inSlYETLO1+I=

Inițiat în sistemul Eximbank Online și autorizat cu Semnătura Digitală

MOTIVUL REFUZULUI:

I.P. "AGENȚIA SERVICII PUBLICE"
Departamentul înregistrare a unităților de drept (DÎUD)

Extras
din Registrul de stat al persoanelor juridice
nr. **195942** din **17.12.2025**

Denumirea completă: **Societatea cu Răspundere Limitată "MEDIST GRUP"**

Denumirea prescurtată: **"MEDIST GRUP" S.R.L.**

Forma juridică de organizare: **Societate cu răspundere limitată**

Numărul de identificare de stat și codul fiscal: **1018600004516**

Data înregistrării de stat: **02.02.2018**

Sediu: **MD-2012, str. Mitropolit Gavriil Bănulescu-Bodoni 25, ap. 33, mun. Chișinău, Republica Moldova**

Genurile de activitate:

1. **Comerţ cu ridicata al produselor farmaceutice;**
2. **Comerţ cu ridicata nespecializat;**
3. **Repararea echipamentelor electronice şi optice;**
4. **Activităţi de testare şi analize tehnice;**
5. **Comerţ cu amănuntul al articolelor medicale şi ortopedice, în magazine specializate;**

Capitalul social: **373026 Lei**

Administrator(i): **ANGHEL GABRIELA-CRISTINA**

Asociați:

1. **"MEDIST IMAGING & P.O.C." S.R.L., partea socială 6244 Euro, ce constituie 33%**
2. **"MEDIST LIFE SCIENCE" S.R.L., partea socială 6244 Euro, ce constituie 33%**
3. **"MEDIST" S.R.L., partea socială 6433 Euro, ce constituie 34%**

Beneficiari efectivi: **MANOLE IONEL, KLUMPNER CATALINA ANA, VLĂDESCU CARMEN, VLĂDESCU SEBASTIAN-ALEXANDRU**

Prezentul extras este eliberat în temeiul art. 34 al Legii nr.220/2007 privind înregistrarea de stat a persoanelor juridice şi a întreprinzătorilor individuali şi confirmă datele din Registrul de stat la data de 17.12.2025

Specialist coordonator
Ana Pîntea
tel. 022-207891

EXIMBANK

BC EXIMBANK SA BC EXIMBANK SA BC EXIMBANK SA BC EXIMBANK SA
BANCA COMERCIALĂ "EXIMBANK" S.A.
SUCURSALA Nr.20
Nr. de ieşire S20/147

21. MAR. 2025

CERTIFICAT

Prin prezentul, B.C. "EXIMBANK" S.A., Sucursala nr.20, confirmă faptul deţinerii de către compania **„MEDIST GRUP" SRL, IDNO 1018600004516**, a următorului cont de decontare în valuta MDL, activ la data de 21.03.2025:

Valuta	Nr. Cont	Cod IBAN
MDL	2251874012MD	MD59EX0000002251874012MD

Certificatul este eliberat pentru a fi prezentat la cerere.

Coordonator, Sucursala nr. 20
Postu Diana

BANCA COMERCIALĂ "EXIMBANK" S.A. SUCURSALA Nr.20 EXIMBANK

Ex.: Belecci Lilia
Tel.: 022 301-244

DECLARAŢIE
privind valabilitatea ofertei

Către: **IMSP Spitalul Clinic Republican „Timofei Moșneaga”**

Stimaţi domni,

Ne angajăm să menţinem oferta valabilă, **privind Achiziționarea Materiale de control extern al calității investigațiilor de laborator pentru anul 2026,** deschisă pentru o durată de 90 (nouăzeci) zile de la deschiderea ofertelor, respectiv până la data de 15/05/2026 (ziua/luna/anul), şi ea va rămâne obligatorie pentru noi şi poate fi acceptată oricând înainte de expirarea perioadei de valabilitate.

Data completării **03.02.2026**

Cu stimă,

Ofertant/candidat

Gabriela-Cristina Anghel

(semnătura autorizată)

MEDIST Grup S.R.L.
Str. Mitropolit Gavriil Bănulescu-Bodoni nr. 25
Oficiul 33, MD-2012 Chișinău, Rep. Moldova
Tel./Fax: +373 22 84 94 95
E-mail: office@medist.md
Web: www.medist.md

IDNO: 1018600004516
TVA: 0508191
BC Victoriabank SA, Filiala nr. 26 Chișinău
IBAN (MDL):MD57VI022242600000269MDL
SWIFT: VICBMD2X469

MEDIST Grup
Soluții pentru sănătate

ISO 9001 SYSTEMA CERTIFICĂM PERFORMANȚA
ISO 14001 SYSTEMA CERTIFICĂM PERFORMANȚA
ISO 13485 SYSTEMA CERTIFICĂM PERFORMANȚA
IAS ACCREDITED Management Systems Certification Body MSCB-173

DECLARAȚIE

Subsemnata Gabriela Anghel, reprezentant împuternicit al MEDIST GRUP S.R.L, cu sediul în mun. Chișinău, str. M.G. Bănulescu-Bodoni 25, Oficiul 33, declar pe propria răspundere că:

- seturile vor fi livrate în ambalaj original, marcat și etichetat de producător.

- datele de identificare (denumirea, numărul lotului, seria, termenii de valabilitate, condițiile de păstrare) ale produsului indicate pe ambalaj vor coincide în mod obligatoriu cu cele de pe etichetele componentelor incluse în set.

Data: 03.02.2026

MEDIST GRUP S.R.L.
DIRECTOARE ADMINISTRATIVĂ
GABRIELA-CRISTINA ANGHEL

MEDIST Grup S.R.L.
Str. Mitropolit Gavriil Bănulescu-Bodoni nr. 25
Oficiul 33, MD-2012 Chișinău, Rep. Moldova
Tel./Fax: +373 22 84 94 95
E-mail: office@medist.md
Web: www.medist.md

IDNO: 1018600004516
TVA: 0508191
BC Victoriabank SA, Filiala nr. 26 Chișinău
IBAN (MDL):MD57VI022242600000269MDL
SWIFT: VICBMD2X469

Certificate of Accreditation

Randox Laboratories Limited

Proficiency Testing Provider No. 0010

is accredited in accordance with International Standard ISO/IEC 17043:2010 – Conformity assessment - General requirements for proficiency testing

This accreditation demonstrates technical competence for a defined scope specified in the schedule to this certificate. The schedule to this certificate is an essential accreditation document and from time to time may be revised and reissued.

The most recent issue of the schedule of accreditation, which bears the same accreditation number as this certificate, is available from www.ukas.com.

This accreditation is subject to continuing conformity with United Kingdom Accreditation Service requirements.

Matt Gantley, *Chief Executive Officer*
United Kingdom Accreditation Service

Initial Accreditation: July 4, 2002
Certificate Issued: December 9, 2019

Scan QR Code to verify

RQ9159

IMMUNOSUPPRESSANT PROGRAMME
PROGRAMME IMUNOSSUPRESSEUR
PROGRAMA IMUNOSSUPRESORES
PROGRAMA DE INMUNOSUPRESORES
PROGRAMMA IMMUNOSOPPRESSORI
PROGRAM LEKI IMMUNOSUPRESYJNE
CHƯƠNG TRÌNH NGOẠI KIỂM ỨC CHẾ MIỄN DỊCH
โปรแกรม IMMUNOSUPPRESSANT
免疫抑制剂计划
İMMÜNOSUPRESANLAR PROGRAMI

ENGLISH

IMMUNOSUPPRESSANT PROGRAMME: RQ9159

CONFIRMATION OF KIT CHARACTERISTICS AND RECEIPT DATE
Please confirm that the correct number of samples are present and that your samples have the appearance as indicated in the CHARACTERISTICS section below. Please confirm that none of the vials are broken and notify your local Randox representative immediately if there are any discrepancies. Finally, please log on to www.riqas.net to confirm the exact date on which you received this kit.

CHARACTERISTICS
The pack contains 6 vials of lyophilised material (6 x 2 ml). The vials are labelled with the sample number.

PREPARATION/STORAGE/STABILITY OF SAMPLES
The samples are sealed under vacuum. Open the vial very carefully, avoiding any loss of material and using a calibrated pipette reconstitute with an accurately measured 2 ml volume of freshly double distilled water at **+20˚C to +25˚C.** Replace the rubber stopper and ensure that samples are dissolved completely by swirling gently (ideally place on a roller for half an hour prior to analysis). Do not shake the vials. We recommend that the samples are run immediately following full reconstitution. The samples should be treated in the same way as patient samples.

SAFETY
Warning: Potentially Biohazardous Material
Human source material from which this product has been derived has been tested at donor level for the Human Immunodeficiency Virus (HIV 1, HIV 2) antibody, Hepatitis B surface Antigen (HbsAg), and Hepatitis C Virus (HCV) antibody and found to be NON-REACTIVE. FDA approved methods have been used to conduct these tests. However, since no method can offer complete assurance as to the absence of infectious agents, this material and all patient samples should be handled as though capable of transmitting infectious diseases and disposed of accordingly.

For IN VITRO use only. Do not pipette by mouth. Exercise the normal precautions required for handling laboratory reagents.

*** IMPORTANT NOTE:** Results must arrive at ***RIQAS*** by **17:00 hrs GMT** on the **FINAL DATE**. If the **RECOMMENDED ANALYSIS DATE** gives insufficient time, we suggest that the sample is analysed earlier to ensure you meet the deadline. Late results will not be accepted after the final date for the next sample.

IMMUNOSUPPRESSANT PROGRAMME/ PROGRAMME IMUNOSSUPRESSEUR / PROGRAMA IMUNOSSUPRESORES / PROGRAMA DE INMUNOSUPRESORES / PROGRAMMA IMMUNOSOPPRESSORI / PROGRAM LEKI IMMUNOSUPRESYJNE
โปรแกรม IMMUNOSUPPRESSANT **/** CHƯƠNG TRÌNH NGOẠI KIỂM ỨC CHẾ MIỄN DỊCH / 免疫抑制剂计划 / İMMÜNOSUPRESANLAR PROGRAMI

RETURN OF RESULTS / RETOUR DES RESULTATS / INVIO DEI RISULTATI / ENVIO DE RESULTADOS / RETORNO DOS RESULTADOS/ PRZESYŁANIE WYNIKÓW / 回复结果 / GỬI TRẢ KẾT QUẢ / SONUÇ GÖNDERİM TARİHLERİ / ODOSLANIE VÝSLEDKOV

CYCLE 8B / CICLO 8B / CYKL 8B / 返回结果周期 8B / CHU KỲ 8B / DÖNEM 8B / CYKLUS 8B

SAMPLE NO / ECHANTILLON NO. / N. CAMPIONE / N° DE MUESTRA / AMOSTRA Nº. / NR PRÓBKI / 样品号 / ตัวอย่างตรวจที่ / MẪU SỐ / ÖRNEK NO / Č. VZORKY	RECOMMENDED ANALYSIS DATE/ DATE RECOMMANDE POUR L' ANALYSE/ DATA DI ANALISI RACCOMANDATA/ FECHA DE ANALISIS RECOMENDADA/ ZALECANA DATA WYKONANIA OZNACZENIA/ 推荐分析日期 / วันที่แนะนำให้ทำการวิเคราะห์ / NGÀY KHUYẾN CÁO PHÂN TÍCH / ÖNERİLEN ÇALIŞMA TARİHİ / ODPORÚČANÝ DÁTUM ANALÝZY	* FINAL DATE/ *DATE LIMITE/ * DATA FINALE/ *FECHA FINAL/ * DATA KOŃCOWA/ *最终日期 * วันสุดท้ายของการส่งผลกลับ / * HẠN CUỐI GỬI TRẢ KẾT QUẢ *SON SONUÇ GÖNDERİM TARİHİ / *FINÁLNY TERMÍN
7	11.09.23	18.09.23
8	09.10.23	16.10.23
9	13.11.23	20.11.23
10	11.12.23	18.12.23
11	15.01.24	22.01.24
12	12.02.24	19.02.24

RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QY
Tel: +44 (0) 28 9442 2413
Email: mail@riqas.com Website: www.randox.com

FRANÇAIS

PROGRAMME IMUNOSSUPRESSEUR: RQ9159

CONFIRMATION DES CARACTERISTIQUES DU KIT ET DE LA DATE DE RECEPTION:
Veuillez vérifier que l'ensemble des échantillons soient présents dans le coffret et que leur apparence est conforme comme indiqué dans la section ci-dessous. De plus assurez-vous qu'aucun des flacons ne soient brisés et en informer immédiatement votre représentant Randox si cela est le cas. Enfin, il est nécessaire de se connecter à www.riqas.net pour confirmer la date exacte à laquelle vous avez reçu ce kit.

CARACTERISTIQUE
Le coffret est composé de 6 flacons de matériel lyophilisé (6 x 2 ml). Le numéro de l'échantillon est indiqué sur l'étiquette du flacon.

PREPARATION/STOCKAGE/STABILITE DES ECHANTILLONS
Les échantillons sont scellés sous vide. Ouvrir le flacon avec précaution, pour éviter la perte de matériel. Utiliser une pipette étalonnée, et mesurer 2 ml avec précision d'eau bidistillée entre +20 et+25°C. Replacer le bouchon en caoutchouc et s'assurer que les échantillons sont dissous complètement en procédant par retournements successifs (idéalement, placer sur un rouleau pendant une demi-heure avant l'analyse). Ne pas secouer les flacons. Nous vous recommandons d'analyser les échantillons immédiatement après le temps de reconstitution. Les échantillons doivent être traités comme vos échantillons patients.

SÉCURITÉ
Produit à risque biologique
Ce matériel d'origine humaine, dont les donneurs ont été testés pour la présence d'anticorps de ''l'Human Immunodeficiency Virus'' (HIV 1, HIV 2), l'antigène de surface de l'Hépatite B (HbsAg), et d'anticorps du virus de l'Hépatite C (HCV) et ont été trouvés négatifs. Ces tests ont été effectués par des méthodes approuvées par la FDA (US Food and Drug Administration). Cependant, aucun test ne pouvant apporter une garantie totale sur le caractère non infectieux de ces produit.

Réservé uniquement pour un usage **IN VITRO**. Ne pas pipeter à la bouche. Respecter les précautions d'usage pour la manipulation des réactifs de laboratoire.

*** NOTE IMPORTANTE:** Les résultats ***RIQAS*** doivent parvenir au Département ***RIQAS*** au plus tard le lundi midi selon la **DATE FINALE**. Nous vous recommandons d'analyser les échantillons quelques jours avant cette date finale. Les résultats en retard ne seront pas acceptés après la date finale de l'échantillon suivant. Vous pouvez envoyer vos résultats via Riqasnet ou par e.mail à l'adresse suivante: mail@riqas.com.

PORTUGUÊS

PROGRAMA IMUNOSSUPRESORES: RQ9159

CONFIRMAÇÃO DAS CARACTERÍSTICAS DO KIT E DATA DE RECEPÇÃO
Agradecemos-lhe que confirme que recebeu o número correcto de amostras e que estas teêm o aspecto descrito na secção CARACTERÍSTICAS deste documento. Verifique também, se nenhum dos frascos está partido e notifique o seu representante local da Randox caso encontre alguma discrepância. Finalmente, aceda ao www.riqas.net para confirmar a data exacta em que recepcionou este kit.

CARACTERÍSTICAS
O Kit contém 6 frascos com material liofilizado (6 x 2 ml). Os frascos estão rotulados com o número da amostra.

PREPARAÇÃO/CONSERVAÇÃO/ESTABILIDADE DAS AMOSTRAS
As amostras encontram-se fechadas em vacuo. Abra o frasco cuidadosamente, evitando perdas de material e, usamdo uma **pipeta calibrada**, reconstitua com a **exactamente** 2 ml de água recentemente destilada a **+20˚C- +25˚C**. Reponha a rolha de borracha e dissolva completamente o material agitando suavemente (pode colocar os frascos no agitador durante 30 minutos antes da análise).Recomendamos que faça os testes imediatamente após a reconstituição. As amostras devem ser tratadas da mesma forma que as amostras dos doentes.

SEGURANÇA
Aviso: material com potencial risco biológico
O material de origem humana usado, foi testado ao nível do dador para os vírus HIV 1 e HIV 2 , assim como para HbsAg e HCV. Os métodos usados para efectuar estes testes têm a aprovação do FDA, contudo e uma vez que nenhum método pode garantir totalmente a ausência de agentes infecciosos, este material deve ser tratado como potencialmente perigoso e eliminado respeitando as boas praticas laboratoriais.

Apenas para IN VITRO. Não pipete com a boca e respeite as Boas Praticas Laboratoriais para o manuseamente de material potencialmente contaminado.

*** NOTA IMPORTANTE:** Os resultados têm de chegar ao ***RIQAS*** até ás **17:00 hr GMT** na **DATA FINAL**. Se a **DATA RECOMENDADA PARA ANÁLISE** não der tempo suficiente, sugerimos que a amostra seja analisada mais cedo para garantir o cumprimento da data limite. Resultados atrasados não serão aceites depois a data final da amostra seguinte.

ESPAÑOL

PROGRAMA DE INMUNOSUPPRESORES: RQ9159

CONFIRMACION DE LAS CARACTERISTICAS DEL KIT Y LA FECHA DE RECEPCION.
Por favor, Asegúrese de que ha recibido el numero correcto de muestras y que estas cumplen con la presentación indicada en la sección "CARACTERISTICAS" que encontrara a continuación. Por favor, confirme que ninguna de las muestras ha resultado dañada y contacte a su Representante local de Randox inmediatamente en el caso de que hubiese alguna discrepancia. Por ultimo, Acceda a www.riqas.net para confirmar la fecha exacta en la que recibió el kit.

CARACTERÍSTICAS
El paquete contiene 6 frascos de muestras liofilizadas (6 x 2 ml). Los frascos están marcados con el número de la muestra.

PREPARACIÓN/ ALMACENAMIENTO/ ESTABILIDAD DE LAS MUESTRAS
Las muestras están cerradas al vacío. Abrir el frasco con mucho cuidado, para evitar cualquier pérdida de material y reconstituir con exactamente 2 ml de agua destilada obtenida recientemente y conservada entre +20˚C y +25˚C. Volver a colocar el tapón de goma para cerrar el frasco y asegurarse de que los componentes liofilizados estén completamente disueltos girando el frasco suavemente (idealmente debe ponerlos en una maquina girador durante media hora antes de analizar). No agitar los frascos. Recomendamos que se analice las muestras inmediatamente después de reconstitución. Debe manejar las muestras en la misma manera que las muestras de pacientes.

SEGURIDAD
Advertencia: Material Potencialmente Biopeligroso
El material de base humana de donde vienen estas muestras ha sido analizado, siendo negativo para anticuerpos HIV 1, HIV 2, HbsAg y HCV. Hemos usado métodos aprobados por la FDA para realizar estas pruebas. Sin embargo, ya que ningún método pueda ofrecer una seguridad completa en cuanto a la ausencia de agentes infecciosos, se debe manejar este material y las muestras de pacientes como si fueran capaces de transmitir enfermedades infecciosas y debe tirarlos de manera apropiada.

Sólo para IN VITRO. No pipetear con la boca. Debe seguir las precauciones normales para el manejo de reactivos de laboratorio.

*** NOTA IMPORTANTE:** Los resultados deben arribar a ***RIQAS*** a las **17:00 horas GMT** en la **FECHA FINAL**. Si la **FECHA RECOMENDADA PARA ANALISIS** dada es insuficiente, le sugerimos que analice la muestra antes para asegurarse que la tenga lista en la fecha final. Los resultados tardíos nos serán aceptados después de la fecha final de la siguiente muestra.

ITALIANO

PROGRAMMA IMMUNOSUPPRESSORI: RQ9159

CONFERMA DELLE CARATTERISTICHE DEL KIT E DELLA DATA DI RICEZIONE
Si prega di confermare che sia presente il numero corretto di campioni e che i vostri campioni siano come indicato nella sezione CARATTERISTICHE qui sotto. Confermare che nessuna fiala sia rotta ed informare immediatamente il rappresentante Randox locale se ci fossero delle discrepanze. Infine, si prega di accedere al sito www.riqas.net per confermare la data esatta in cui si è ricevuto questo kit.

CARATTERISTICHE
Il pacco contiene 6 fiale di materiale liofilo (6 x 2 ml). Le fiale sono etichettate con il numero del campione.

PREPARAZIONE/CONSERVAZIONE/ STABILITA' DEI CAMPIONI
I campioni sono chiusi sottovuoto. Aprire la fiala con estrema cautela, evitando qualsiasi perdita di materiale e usando una pipetta calibrata ricostituire con un volume accuratamente misurato di 2 ml di acqua appena bidistillata a **+20˚C to +25˚C.** Rimettere il tappo di gomma e assicurarsi che i campioni siano dissolti completamente agitando delicatamente (l'ideale sarebbe utilizzare un agitatore per mezz'ora prima dell'analisi). Raccomandiamo di dosare i campioni immediatamente dopo la ricostituzione. I campioni devono essere trattati nello stesso modo in cui vengono trattati i campioni di pazienti.

SICUREZZA
Attenzione:materiale potenzialmente pericoloso

Il materiale di origine umana da cui è derivato questo prodotto è stato testato sui donatori, e ha dato ESITO NEGATIVO, per l'anticorpo del virus da Immunodeficienza Umana (HIV 1, HIV 2), per l'Antigene di Superficie del virus dell'Epatite B (HbsAg), e per l'anticorpo del virus dell'Epatite C (HCV). Per questi test sono stati usati metodi approvati dall'FDA.
Poiché nessun metodo di indagine può dare assoluta garanzia di assenza di questi agenti infettivi, si raccomanda di trattare e smaltire il prodotto e tutti i campioni dei pazienti con cautela.

Solo per uso **IN VITRO**. Non utilizzare pipette a bocca. Utilizzare le normali precauzioni necessarie per la manipolazione di reagenti di laboratorio.

*** NOTA IMPORTANTE:** I risultati devono arrivare a ***RIQAS*** entro le 17:00 GMT dell' **ULTIMA DATA**. Se la **DATA RACCOMANDATA PER L'ANALISI** non fornisce tempo a sufficienza, suggeriamo di analizzare il campione prima per essere certi di rispettare la scadenza. Risultati in ritardo non saranno accettati dopo l'ultima data del campione successivo.

POLSKI

PROGRAM LEKI IMMUNSUPRESYJNE: RQ 9159

POTWIERDZENIE CHARAKTERYSTKI ZESTAWU I DATY ODBIORU
Prosimy o potwierdzenie, że zestaw zawiera odpowiednią ilość próbek i Państwa próbki wyglądają tak, jak w podanej poniżej CHARAKTERYSTYCE. Prosimy o potwierdzenie, że żadna z próbek nie jest zbita, a jeśli są jakiekolwiek niezgodności prosimy o niezwłoczne zgłoszenie tego lokalnemu przedstawicielowi.
Następnie prosimy o zalogowanie się na www.riqas.net w celu potwierdzenia dokładnej daty otrzymania zestawu.

CHARAKTERYSTYKA
Opakowanie zawiera 6 fiolki próbek liofilizowanych (6 x 2 ml). Fiolki są oznakowane numerem próbki.

PRZYGOTOWANIE/PRZECHOWYWANIE/STABILNOŚĆ PRÓBEK
Próbki są zamknięte metodą próżniową. Otworzyć fiolkę bardzo ostrożnie, unikając utraty materiału i rekonstytuować w dokładnie odmierzonej objętości 2 ml świeżo podwójnie destylowanej wodzie w temperaturze od **+20 do +25ºC**.Umieścić gumowy korek i upewnić się, czy próbka uległa rozpuszczeniu poprzez delikatne rolowanie (najlepiej umieścić próbkę na mieszadle na pół godziny przed oznaczeniem).Proszę nie wstrząsać fiolką. Wskazane jest wykonanie oznaczenia natychmiast po wykonaniu powyższej rekonstytucji.

Zaleca się aby postępować z próbką tak samo jak z materiałami pobranymi od pacjentów.

BEZPIECZEŃSTWO
Ostrożnie: Materiał potencjalnie szkodliwy biologicznie.
Próbki zawierają krew ludzką. Każdy dawca został przebadany na obecność przeciwciał wirusów HIV1 i HIV2 oraz antygenu powierzchniowego zapalenia wątroby typu B (Hbs Ag) i typu C (HCV). Próbki dały wynik negatywny. Przeprowadzone badania są potwierdzone przez FDA. Jednakże, żadna metoda nie daje całkowitej pewności nieobecności czynników zakaźnych, dlatego ten materiał i wszystkie próbki pobrane od pacjentów powinny być traktowane jako potencjalne źródło chorób zakaźnych.

Tylko do *in vitro*. Nie należy pipetować ustami. Zachować ostrożność wymaganą przy używaniu odczynników laboratoryjnych.

UWAGA:** Wyniki muszą dotrzeć do ***RIQAS do godziny **17:00 czasu GMT w dniu DATY FINALNEJ**. **Termin ten dotyczy użytkowników programu RIQASnet.** Jeżeli **ZALECANA DATA OZNACZENIA** jest zbyt późna, sugeruje się przeprowadzenie wcześniejszej analizy, aby uzyskać czas na przesłanie wyników. Spóźnione wyniki przesłane po dacie finalnej następnej próbki nie zostaną przyjęte.

ภาษาไทย

โปรแกรม **IMMUNOSUPPRESSANT**: RQ9159

ยืนยันคุณลักษณะชุด kit **และวันที่ได้รับชุด** kit

โปรดยืนยันว่าจำนวนของตัวอย่างถูกต้อง เป็นตัวอย่างในปัจจุบันและตัวอย่างของท่านมีลักษณะตามที่ระบุไว้ในคุณลักษณะด้านล่าง

โปรดยืนยันว่าไม่มีขวดแตกและให้แจ้งตัวแทนจำหน่ายของท่านทันทีหากมีความผิดปกติใด ๆ โปรดเข้าสู่ระบบ www.riqas.net เพื่อยืนยันวันที่ท่านได้รับชุดkit

คุณลักษณะ

ใน 1 กล่อง ประกอบด้วยตัวอย่างที่เป็นผงแห้งบรรจุในขวดขนาด 2 มิลลิลิตร จำนวน 6 ขวด (6 x 2 ml.) โดยแต่ละขวดจะมีหมายเลขตัวอย่างระบุไว้ที่ข้างขวด

การเตรียมตัวอย่างตรวจ / การเก็บรักษา / ความเสถียรของตัวอย่าง

ตัวอย่างปิดผนึกภายใต้สุญญากาศ เปิดแต่ละขวดอย่างระมัดระวัง หลีกเลี่ยงการสูญเสียของตัวอย่าง และใช้ไปเปตที่แคลิเบรทแล้ว ละลายตัวอย่างด้วยfreshly double distilled water 2 มิลลิลิตร ที่อุณหภูมิ 20-25 ºC ปิดจุกยางปิดจุกยางและให้แน่ใจว่าตัวอย่างมีการละลายอย่างสมบูรณ์โดยการหมุนขวดเป็นวงกลมอย่างช้า (swirling) (วางอยู่บน roller ครึ่งชั่วโมงก่อนทำการวิเคราะห์) ห้ามเขย่าขวด เมื่อละลายอย่างสมบูรณ์แล้วให้ทำการวิเคราะห์ตัวอย่างทันที ควรทำการตรวจวิเคราะห์เช่นเดียวกับการตรวจตัวอย่างผู้ป่วย

ความปลอดภัย

ข้อควรระวัง : Potentially Biohazardous Material

ตัวอย่างตรวจได้มาจาก human source ของผู้บริจาคโลหิต ซึ่งได้ทำการตรวจว่ามีความปลอดภัยจากแอนติบอดีของไวรัส HIV (HIV1, HIV2) HBs Ag และ HCV Antibody โดยมีผลการตรวจเป็น Non-Reactive และได้ใช้วิธีการที่ได้รับการพิสูจน์จาก FDA ในการตรวจวัด test ต่างๆ อย่างไรก็ตามไม่มีวิธีการใด ที่จะสามารถให้ความมั่นใจได้ว่าจะปลอดภัยจาก infectious agents ดังนั้นควรจะทำการตรวจวิเคราะห์ตัวอย่าง และ ตัวอย่างจาก ผู้ป่วยด้วยความระมัดระวัง

สำหรับ IN VITRO เท่านั้น อย่าเปตทางปาก ข้อควรระวังให้ปฏิบัติตาม normal precautions สำหรับน้ำยาวิเคราะห์

หมายเหตุ สำคัญผลจะต้องถึง *RIQAS* ในเวลา 17.00 hrs. GMT ของวันสุดท้ายของการส่งผลกลับ (Final Date) ขอแนะนำให้ทำการวิเคราะห์ตัวอย่าง ก่อนจะถึงวันสุดท้ายของการส่งผลกลับ (Final Date) LATE RESULTS หรือการส่งผลช้า จะไม่ได้รับการประเมิน ถ้าส่งผลหลังจาก Final Date ของ sample ถัดไป

TIẾNG VIỆT

CHƯƠNG TRÌNH NGOẠI KIỂM ỨC CHẾ MIỄN DỊCH: RQ9159

XÁC NHẬN VỀ ĐẶC ĐIỂM CỦA BỘ KIT VÀ NGÀY NHẬN MẪU
Xin hãy xác nhận đúng số lượng mẫu và bề mặt ngoài của mẫu giống như đặc điểm nêu phía dưới. Hãy xác nhận không có mẫu nào bị vỡ và thông báo cho đại diện phân phối ngay lập tức nếu xuất hiện dấu hiệu khác thường của mẫu. Cuối cùng, hãy đăng nhập vào www.riqas.net để xác nhận ngày bạn nhận được mẫu.

ĐẶC ĐIỂM
Mỗi hộp bao gồm 6 lọ dạng đông khô, mỗi lọ 2ml và được dán nhãn số theo thứ phân tích.

CHUẨN BỊ/BẢO QUẢN/ĐỘ BỀN CỦA MẪU
Lọ mẫu được đóng nắp chân không. Mở nắp lọ cẩn thận tránh làm thất thoát, pha loãng với chính xác 2ml nước cất hai lần ở **+20˚C – +25˚C**. Đậy nút cao su và đảm bảo rằng mẫu được hòa tan hoàn toàn bằng cách xoay nhẹ nhàng (tốt nhất là để trên máy lắc trộn trong 30 phút trước khi phân tích). Chú ý không được lắc mạnh. Chúng tôi khuyến cáo mẫu nên được phân tích ngay sau khi thực hiện đầy đủ các bước hoàn nguyên. Mẫu được xử lý và phân tích giống mẫu bệnh nhân.

ĐỘ AN TOÀN
Cảnh báo: Khả năng có độc tính sinh học với nguồn vật liệu
Mẫu có nguồn gốc từ người và đều được kiểm tra không có phản ứng với kháng thể HIV (HIV 1 & HIV 2), HbsAg, HCV. Phương pháp kiểm tra được chấp nhận bởi tổ chức FDA. Tuy nhiên không có phương pháp kiểm tra nào có thể đảm bảo tuyệt đối sự âm tính của tác nhân truyền nhiễm. Để bảo đảm an toàn tuyệt đối, mẫu này và toàn bộ mẫu bệnh nhân phải được thao tác xử lý giống như mẫu truyền nhiễm.

Chỉ dùng cho phân tích trong ống nghiệm. Không được hút mẫu bằng miệng. Tuân thủ các khuyến cáo thông thường yêu cầu trong quy trình xử lý hoá chất phòng xét nghiệm.

LƯU Ý QUAN TRỌNG:
Kết quả phân tích phải được gửi đến cho RIQAS trước 17:00 GMT ngày hạn chót gửi trả kết quả. Phòng xét nghiệm nên phân tích mẫu sớm trước ngày khuyến cáo phân tích mẫu nếu cần để đảm bảo thời gian gửi trả kết quả. Kết quả phân tích trễ sẽ không được chấp nhận sau hạn chót gửi trả kết quả của mẫu tiếp theo.

中文

免疫抑制剂计划:RQ9159

确认试剂盒特性和接收日期

请确认样品的数量正确**及外**观如下面特性描述一致。请确认没有小瓶破损，**如果有任何差异**请立即通知当地的朗道的代表。**最后**，请登录 www.riqas.net **确**认您用来接收该试剂盒的确切**日期**

特性
此试剂盒包含 6 瓶冻干材料（6×2 毫升）。每瓶上标注了样本编号。

样本的配制/储存/稳定性
样本是在真空密封状态。小心打开每个小瓶，避免损失任何材料，在+20℃～+25℃环境下使用经校准的移液器准确测量的 2ml 新鲜蒸馏水来复溶每瓶样本。除去橡胶塞，并确保样本通过涡旋轻轻完全溶解（理想状态下在分析前放在滚筒上半小时）。不要摇晃瓶子。我们建议完全复溶后立即检测样本。样本处理应与患者标本相同。样本不使用时，

安全
警告：具有潜在生物安全危险的材料
这款产品中所使用的有献血者获得的人源物质已经进行了人类免疫缺陷病毒（HIV1，HIV2）**抗体、乙肝表面抗原**（HBsAg）**和丙型肝炎病毒**（HCV）**抗体**检测，结果为阴性。这些试验使用的是 FDA **批准的方法。然而，由于感染性病原体的缺失，没有方法能**够完全保证安全，所以这种物质和所有患者标本应如同传染病传播的处理和**做出相**应的处置。

用于体外诊断。不要用嘴吸允。练习进行处理，需要实验室试剂的常规注意事项。

重要提示**：结果必须在最后期限 **17:00GMT** 反馈给 ***RIQAS。**如果推荐分析日期**给出**的**时间**不足**，**我**们建议**提早**进行样品分析，以确保您复合**最后期限**。晚于截止日期的结**果将不被接受**。

TÜRKÇE

IMMÜNOSUPRESANLAR PROGRAMI: RQ9159

KİT ÖZELLİKLERİNİN VE ULAŞMA TARİHİNİN DOĞRULANMASI

Lütfen doğru sayıda örneğin bulunduğunu ve örneklerin görünüşlerinin aşağıda ÖZELLİKLER bölümünde belirtildiği gibi olduğunu doğrulayınız. Lütfen şişelerden hiç birinin kırık olmadığını doğrulayınız ve eğer herhangi bir uygunsuzluk varsa derhal yerel RANDOX sorumlunuzu uyarınız. Son olarak, lütfen www.riqas.net 'e giriş yaparak bu kiti hatasız teslim aldığınız tarihi doğrulayınız.

ÖZELLİKLER
Paket, 6 şişe liyofilize materyali içerir (6 x 2 ml). Şişeler; örnek numaraları ile etiketlenmiştit.

NUMUNE HAZIRLAMA / DEPOLAMA / NUMUNELERIN STABILITESI
Örnekler vakumlanarak ambalajlanmıştır. Şişeyi, herhangi bir materyal kaybı olmayacak şekilde dikkatlice açınız ve kalibre edilmiş bir pipetle tam 2 ml'lik hacimde taze distile su ile **+20˚C -+25˚C**'de sulandırınız**.** Plastik tıpayı yerleştiriniz ve hafifçe çevirerek örneklerin tam olarak çözünmesini sağlayınız. (İdeali analizden yarım saat önce bir karıştırıcı üzerine koymaktır). Çalkalamayınız. Örnekler tam olarak çözününce hemen çalışmanız önerilmektedir. Örneklere, hasta örnekleri ile aynı şekilde muamele edilmelidir.

GÜVENLİK
Uyarı: Potansiyel olarak biyolojik tehlikeli madde
Bu ürünün elde edildiği insan kaynaklı materyal donor seviyesinde İnsan İmmünyetmezlik Virüsü (HIV 1, HIV 2) antikoru, Hepatit B yüzey Antijeni (HbsAg), ve Hepatit C Virüs (HCV) antikoru açısından test edilmiş ve NON-REAKTİF olarak bulunmuştur. Bu testler için FDA onaylı metotlar kullanılmıştır. Fakat yine de, hiç bir metot enfeksiyon ajanlarının yokluğu için tam garanti vermediğinden bu materyal ve tüm hasta örnekleri muhtemel enfeksiyon hastalığı taşıyıcısı varsayılarak çalışılmalı ve uygun şekilde atığa gönderilmelidir.

Sadece IN VITRO kullanım içindir.Ağızla pipetleme yapmayınız. Laboratuvar reaktiflerinin örneklenmesi için gerekli normal önlemleri uygulayınız.

*** ÖNEMLİ NOT:** Sonuçlar, RIQAS'a **SON SONUÇ GÖNDERİM TARİHİ'**nde saat **17:00**'de ulaşmış olmalıdır.Eğer **ÖNERİLEN ANALİZ TARİHİ** sizin için uygun değilse, sonuç gönderim tarihine yetişmesi için için örneği daha erken analiz etmenizi öneririz. Geç sonuçlar, bir sonraki örneğin son sonuç gönderim tarihi sonrasında kabul edilmeyecektir.

SLOVENSKY

IMMUNOSUPPRESSANT PROGRAMME: RQ9159

POTVRDENIE CHARAKTERISTIKY KITU A DÁTUMU DORUČENIA
Prosím potvrďte doručenie správneho čísla vzorky a potvrďte, či vzhľad vzoriek zodpovedá charakteristike opísanej v sekcii nižšie. Prosím potvrďte, že žiadne fľaštičky nie sú rozbité, v opačnom prípade okamžite kontaktuje svojho obchodného zástupcu. Po prihlásení na www.riqas.net potvrďte a zadajte presný dátum, kedy Vám bol kit doručený.

CHARAKTERISTIKA
Balenie obsahuje 6 fľaštičiek lyofilizovaných vzoriek (6 x 2 ml). Fľaštičky sú označené číslom vzorky.

PRÍPRAVA/SKLADOVANIE/STABILITA VZORIEK
Fľaštička je vákuovo uzatvorená. Otvorte fľaštičku veľmi opatrne, vyhnite sa stratám materiálu a použitím **nakalibrovanej pipety** rekonštitujte presne **2 ml** objemu čerstvo destilovanej vody pri teplote **+20˚C to +25˚C.** Zatvorte gumenou zátkou a jemným vírením sa uistite, že vzorky sú úplne rozpustené (ideálne umiestnite na miešadlo, roler, na pol hodinu pred samotnou analýzou). Netraste fľaštičkami. Odporúčame analýzu vzoriek okamžite po úplnej rekonštitúcii. So vzorkami zaobchádzajte rovnakým spôsobom ako s pacientskými vzorkami.

BEZPEĆNOSŤ
Upozornenie: Potenciálne biohazardný materiál

Tento materiál je vyrobený z ľudského zdroja a bol testovaný na úrovni darcu na Human Immunodeficiency Virus (HIV 1, HIV 2) protilátky, Hepatitídu B povrchový antigen (HbsAg), a protilátky Hepatitídy C (HCV) a bol preukázaný ako NEREAKÍVNY. Boli použité metódy schválené federáciou FDA. Keďže žiadna metóda nezabezpečí úplnu dôveryhodnosť, zaobchádzajte s materiálom a všetkým vzorkami pacientov ako so vzorkami, ktoré sú schopné prenášať infekčné ochorenia.

Iba na **IN VITRO** použitie. Neipetujte ústami. Vykonajte bežné opatrenia vyžadované pri manipulácii s laboratórnymi reagenciami.

* POZNÁMKA: **Výsledky musia byť odoslané do** *RIQAS* **do** 17:00 Hod GMT **vo** FINÁLNY DÁTUM**. Ak** ODPORÚČANÝ DÁTUM ANALÝZY **neposkytuje dostatočný čas, odporúčame analýzu vzorky skôr, aby sa zabezpečilo dodržanie termínu. Výsledky prijaté po finálnom termíne nebudú akceptované.**

July 2023

RANDOX Laboratories Ltd., 55 Diamond Road, Crumlin, Co. Antrim, United Kingdom, BT29 4QY
Tel: +44 (0) 28 9442 2413
Email: mail@riqas.com Website: www.randox.com

RANDOX

RANDOX INTERNATIONAL QUALITY ASSESSMENT SCHEME

RIQAS

RANDOX
QUALITY CONTROL

RIQAS

THE LARGEST INTERNATIONAL EQA SCHEME WITH OVER 75,000 LAB PARTICIPANTS

Whilst every attempt is made to ensure that information is accurate and up-to-date, some information is subject to change.
Please contact **marketing@randox.com** for current details.

BENEFITS

Delivering a comprehensive yet cost effective EQA solution, RIQAS will help meet regulatory requirements and increase confidence in test system accuracy.

Large Database of Users

- A high level of participation means peer group numbers are maximised whilst ensuring availability of data for a wide range of instruments and methods.

User-friendly Reports

- Simple, one page per parameter format, enables at-a-glance performance assessment, saving valuable laboratory time.
- Complimentary multi-instrument and interlaboratory reports allow comparative performance assessment of all laboratory systems and multiple connected laboratories.
- End-of-Cycle reports, summarising performance compared to the previous cycle, allows you to identify improvements in quality over time.

Cost Effective

- Our extensive range of multi-analyte programmes will reduce the number of individual programmes required to cover your test menu, saving both time and money.
- Reduced parameter options for selected programmes offer greater flexibility, ensuring suitability for laboratories of all sizes and budgets.
- Register up to five instruments per programme (volume permitting) at no extra cost for comparative performance assessment.

Frequency

- Frequent reporting allows early identification of system errors and implementation of any necessary corrective actions with minimum disruption to the lab.
- With a turnaround of less than 72 hours for most reports, corrective action can be implemented earlier, potentially reducing costly errors with patient results.

High Quality Samples

- Samples spanning clinically relevant levels allow identification of concentration related biases, helping to ensure accurate instrument performance.
- Human samples free from interfering preservatives increase confidence that EQA performance mirrors the performance of patient samples.
- Reference method values are provided in the Clinical Chemistry programme for selected parameters and lots, while for the Immunosuppressant programme they are provided for all parameters and lots.

Highly Accredited

- Programmes accepted by National and International accreditation bodies worldwide.
- Participant certificates provide evidence of participation in a reputable EQA scheme.

EQA

RIQAS is the largest international EQA scheme in the world. It is used by more than 75,000 laboratory participants in 136 countries. 36 programmes are currently available.

RIQAS Programmes

- Ammonia/Ethanol
- Anti-Müllerian Hormone (AMH)
- Anti-TSH Receptor
- Blood Gas
- BNP
- Cardiac
- Cardiac Plus
- Cerebrospinal Fluid (CSF)
- Clinical Chemistry
- Coagulation
- CO-Oximetry
- CYFRA 21-1
- Cytokines
- ESR
- Glycated Haemoglobin (HbA1c)
- Haematology
- Human Urine
- Immunoassay
- Immunoassay Speciality 1
- Immunoassay Speciality 2
- Immunosuppressant Drugs
- Lipids
- Maternal Screening
- Microbiology (Bacterial Identification)
- Neonatal Bilirubin
- Serology (Anti-SARS-CoV-2)
- Serology Epstein Barr Virus (EBV)
- Serology (HIV/Hepatitis)
- Serology (Syphilis)
- Serology (ToRCH)
- Serum Indices
- Specific Proteins
- Sweat Testing
- Therapeutic Drugs
- Urinalysis
- Urine Toxicology

Accreditation

- RIQAS provides certificates as proof of EQA participation and performance for laboratory accreditation purposes.
- RIQAS is a UKAS accredited Proficiency Testing Provider, No. 0010, and is accredited to ISO/IEC 17043:2010, 'Conformity Assessment- General Requirements for Proficiency Testing'.
- Accreditation to ISO/IEC 17043:2010 highlights the superior quality and excellence of RIQAS.

UK Performance Surveillance

- Recognised by the Quality Assurance in Pathology Committee (QAPC).
- Recognised by various National Quality Assurance Advisory Panels (NQAAP).

Independent Advisory Panel

RIQAS participants have access to an independent advisory panel consisting of scientific and clinical experts. This ensures professional and ethical conduct of the scheme and participant confidentiality.

RIQAS support staff are on hand to offer advice and troubleshoot technical queries.

RIQAS REPORTS

RIQAS reports are presented in a user-friendly, one page per parameter format. This allows easy interpretation of your analytical performance.

RIQAS Reports

- Statistical breakdown by all methods, your method and, where applicable, your instrument, including running means for the last 10 samples.
- Compare your instrument group, method group and all methods using the histogram.
- Identify trends, biases and precision problems using the visual charts.
- The Target Score chart uniquely grades your performance in a moving window over the last 20 samples, including the previous cycle.
- At-a-glance summary page for all parameters in the programme.
- Compare your result with statistically robust consensus means.
- Identify acceptable and poor performance using fit-for-purpose performance indicators:
  - SDI
  - %Deviation
  - Target Score



Summary CSV Files

It is possible to receive an additional summary of your report statistics, acceptable limits and performance indicators as a .csv file for every sample ***(available for quantitative reports only)***.

Multi-Instrument Reports

Laboratories can register up to five instruments at no extra cost. Individual reports for each instrument plus a unique multi-instrument report are provided. The multi-instrument report plots the performance of each individual instrument on a single, colour coded Levey-Jennings chart, ensuring instant identification of any differences in instrument performance. Additional sample packs may be ordered as required if volume supplied is insufficient for the registered instruments.

Laboratory Group Reports

The group reporting facility enables laboratory groups or chains to monitor the performance of satellite sites. Each affiliated laboratory will receive their individual reports with the group supervisor also receiving a summary report comparing each laboratory in the network.

WEB-BASED DATA TRANSFER

RIQAS.Net offers easy, direct access for the submission of results and retrieval of reports direct from the RIQAS host server.

- Available in multiple languages.
- Confidentiality and security is maintained through the use of password protected access.
- Submit current, corrected and future results (normal policies apply), directly into the RIQAS database. Receipt of results is confirmed by e-mail.
- Multi-lingual registration identifier provides simple identification of multiple registrations.
- Additions and changes to assay details can be made quickly and easily online.
- Requests for new method, instrument and reagent codes can be made online.
- Reports are emailed in PDF format as soon as they are prepared.
- Reports for the previous two cycles can be downloaded from the website.
- View, print, store or distribute reports as you wish.
- Update your laboratory's certificate of participation details in multiple languages.
- All that is required is web access, Adobe Reader (for viewing reports) and a valid password to access the system.
- No additional software required.





PARTICIPATION IN RIQAS

Participation in RIQAS follows these simple steps:

1 Order your RIQAS programmes through your local Randox Office or Distributor. Register the instruments and methods used in your lab on RIQAS.net or by completing the enrolment document. Enrolment documents are available from riqas.com and should be submitted 3 weeks before the cycle starts. Check RIQAS policies in method questionnaire.

2 Receive a set of numbered samples along with a username/ password to access RIQAS.Net.

Analyse the sample on the recommended date, carefully following the instructions for use. 3

4 Enter your results via RIQAS.Net and submit before the final deadline.



5 Receive report by email and review to assess performance.

6 Receive an end-of-cycle report, a certificate of acceptable performance and a certificate of participation at the end of the cycle, provided that more than half results are returned.

7 Method changes and registration of additional parameters can be submitted via RIQAS.Net.

STANDARD REPORT

Performance data is presented in a one page format with up to seven sub-reports.



1	**Text Section Chart:**	Statistics for all methods, your method and instrument group (programme specific).
2	**Histogram Chart:**	Method and instrument comparison.
3	**Multi-Method Stat Section Chart:**	Enables assessment of the performance of each method.
4	**Levey-Jennings Chart:**	Details features of your laboratory's performance.
5	**Target Score Chart:**	This unique chart provides a numerical index of performance, allowing at-a-glance assessment.
6	**%Deviation by Sample Chart:**	Helps to identify trends and shifts in performance.
7	**%Deviation by Concentration Chart:**	Rapid assessment of concentration related biases.

TEXT SECTION

The text section summarises the statistical information for each parameter.



RIQAS performance indicators include SDI, Target Score and %Deviation.

Acceptable performance criteria:

SDI < 2
Target score ≥ 50
%Deviation ≤ defined acceptable limits

1. Report is presented in your chosen unit.
2. Number of returned results used to generate Mean for Comparison.
3. Average value of all laboratories' results.
4. Coefficient of Variation.
5. Uncertainty associated with the Mean for Comparison.

   $$U_m = \frac{1.25 \times SD}{\sqrt{n}}$$
6. SDPA = Standard Deviation for Performance Assessment, calculated from the Target Deviation for Performance Assessment (TDPA) and the Mean for Comparison.

   $$SDPA = \frac{TDPA \times \text{Mean for Comparison}}{\text{t-value} \times 100}$$

   t-value = factor which represents the % of poor performers reflected in the TDPA (t-value ~ 1.645 when ~10% laboratories achieve poor performance), SDPA is combined with U_m, where appropriate.

   If U_m > (0.3 x SDPA) then $SDPA_{adjusted} = \sqrt{(U_m^2 + SDPA^2)}$ and the reported value is suffixed with "a"

   If U_m is less than (0.3 x SDPA) then $SDPA_{adjusted}$ = SDPA
7. After statistical reduction, some results are excluded from the mean for comparison.
8. Ideally this will be your instrument group mean. If N<5 for instrument group, your method group mean is selected as Mean for Comparison.
9. Standard Deviation Index = $\frac{\text{Your Result - Mean for Comparison}}{SDPA_{adjusted}}$
10. Running Mean average of the last 10 performance indicators is used to monitor performance over time and concentration range.
11. Target Score - The closer a value is to 120, the better the performance.

    $$TS = \log_{10}\left(3.16 \times \frac{TDPA}{|\%Dev|}\right) \times 100$$
12. %Deviation from the Mean for Comparison -

    $$\%Dev = \frac{\text{Your Result - Mean for Comparison}}{\text{Mean for Comparison}} \times 100$$

    The closer the value is to zero, the better the performance.
13. Biological Variation - Not currently available - please review online.
14. Performance limit set for this parameter.
15. Reference values quoted for information purposes, where applicable.

HISTOGRAM

The Bar Graph is intended as a quick visualisation of how your lab's result compares to the method mean, instrument mean and all method mean.

All methods

Your method group

Your instrument group (programme specific)



1. Total of 1126 laboratories reported values between 106.55 & 108.15.
2. 200 laboratories reported values between 101.77 & 103.36 in your method group.
3. RIQAS reports show your unit of measurement.
4. Your result is indicated by the black triangle.
5. 41 laboratories reported values between 111.35 & 112.94 in your instrument group.

MULTI-METHOD STAT SECTION

This section provides an easy way of assessing the performance of other methods used to analyse the parameter in question.

Method	N	Mean	CV%	U_m
Hexokinase	3524	108.234	2.9	0.07
Glucose oxidase	2673	108.474	5.5	0.14
Ortho Vitros MicroSlide Systems	251	105.036	2.3	0.19
Glucose dehydrogenase	63	107.832	3.5	0.59
GOD/02-Beckman method	37	106.425	2.5	0.55
Other Dry Chemistry	27	108.360	6.3	1.64
Agappe - GOD-PAP	21	109.727	3.7	1.11
Oxygen electrode	17	106.666	1.3	0.43
Vitros, DT60/DT60 II	3	105.595	3.9	2.99

LEVEY-JENNINGS CHART

SDIs reflect laboratory performance in relation to fit-for-purpose SDPAs and are useful to monitor performance over time. Acceptable performance is SDI < 2.



1. The Mean for Comparison for each sample is indicated at the top of the chart. This allows easy assessment of concentration related bias:
   - I: Instrument mean
   - M: Method mean
   - A: All method mean
2. This line indicates a change in registration details for this parameter.
3. Your SDI (Standard Deviation Index).
4. Sample number.
5. N = No result returned in time for this registration\sample.
6. C = Corrected results will be accepted for non-analytical errors. Corrected results will be accepted up to 4 weeks after the final submission deadline, on application, with evidence of analysis. Late results are only accepted if there has been a Randox error.

   R = Incorrect results can be removed retrospectively on request.

TARGET SCORE CHART

The Target Score (TS) allows you to assess your performance at a glance. The TS relates the %Deviation of your result from the Mean to a Target Deviation for Performance Assessment (TDPA). TDPAs are set to encourage participants to achieve and maintain acceptable performance. TDPAs are fit-for-purpose performance criteria which are set taking guidance from ISO/IEC17043, ISO13528 and IUPAC. Target Deviations for Performance Assessment are also used to calculate the Standard Deviation for Performance Assessment (SDPA).



1. This is the upper deviation limit of performance for this parameter. TDPAs are reviewed regularly and deemed fit for purpose by the RIQAS Advisory Panel.
2. High scores ≥50 in the lighter shaded area represent acceptable, good or excellent performance.
3. Heavy shading for values 10 to 50 signifies poor performance.

%DEVIATION CHARTS

The %Deviation by sample chart helps to identify trends and shifts in performance.

$$\%\text{Deviation} = \frac{\text{Your Result - Consensus Mean}}{\text{Consensus Mean}} \times 100\%$$



1. %Deviation from Mean for Comparison.
2. Plot of Running Mean %Deviations (average of the last 10 %Deviations for the sample indicated).
3. Acceptable limits of performance. These are defaulted to RIQAS TDPAs but can be set to e.g. biological variation or regulatory requirement on request.

The %Deviation by concentration chart enables rapid assessment of concentration related biases. Biases at low or high concentrations can be easily determined.



1. Current sample indicated by square.
2. %Deviation at specific concentration.

SUMMARY PAGE

Located at the back of the RIQAS Report, the Summary Page collates the key information, allowing participants to review the performance of all parameters at-a-glance.

Analyte	Mean for Comparison	Your Result	SDI	RMSDI	%DEV	RM%DEV	TS	RMTS	Performance
Albumin	2.120	2.230	1.00	0.37	5.2	2.0	72	107	
Alkaline Phosphatase	17.705	19.000	0.61	-0.27	7.3	-2.9	93	105	
ALT (GPT)	12.387	12.000	-0.33	-0.47	-3.1	-3.8	119	103	
Amylase, Total	20.454	22.000	0.72	-0.29	7.6	-2.5	86	103	
AST (GOT)	11.976	11.000	-0.86	-0.03	-8.2	-0.4	78	100	
Bicarbonate	8.203	6.900	-1.48	0.15	-15.9	1.5	54	98	
Bilirubin, Direct	0.251	0.380	***2.57***	2.64	***51.3***	47.2	***31***	29	▲
Bilirubin, Total	0.701	0.640	-0.91	-0.29	-8.8	-2.9	76	101	
Calcium	6.074	6.020	-0.19	-0.40	-0.9	-1.8	120	92	
Chloride	76.353	77.000	0.30	-0.28	0.8	-0.8	120	98	
Cholesterol	112.696	110.000	-0.55	0.05	***2.4***	0.2	97	115	
CK, Total	111.659	111.000	-0.08	0.35	-0.6	2.5	120	107	
Creatinine	0.607	0.620	0.27	0.06	2.1	0.5	120	117	
Glucose	36.429	36.000	-0.26	-0.84	-1.2	-3.7	120	82	
HDL-Cholesterol	98.836	102.000	0.21	-0.04	3.2	-0.4	120	113	
Iron	97.374	99.000	0.28	0.01	1.7	0.1	120	114	
Lactate		No Result		Too Few		Too Few	N/A	N/A	
LD (LDH)	85.894	87.000	0.11	-0.70	1.3	-6.3	120	89	
Magnesium	1.313	1.390	0.79	-0.07	5.8	-0.5	82	107	
Phosphate, Inorganic	1.451	1.540	1.02	0.02	6.1	0.1	71	112	
Potassium	1.770	1.840	1.10	-0.25	3.9	-0.7	67	99	
Protein, Total	3.850	3.830	-0.11	0.07	-0.5	0.3	120	114	
Sodium	112.537	114.000	0.58	-0.01	1.3	-0.0	95	104	
TIBC	133.143	133.000	-0.01	-0.01	-0.1	-0.1	120	117	
Trig Total	23.626	24.000	0.18	-0.09	1.6	-0.6	120	114	
Urea	5.872	5.000	***-2.02***	-0.57	***-14.9***	-4.0	***41***	95	▲
Uric Acid (Urate)	3.135	3.100	-0.20	-0.44	-1.1	-2.4	120	107	
				ORMSDI -0.05		**ORM%DEV 0.8**		**ORMTS 102**	

1. Red triangle appears when all performance indicators (SDI, %DEV and TS) exceed acceptable performance, i.e: when
   SDI >= 2
   TS < 50
   %DEV > acceptable limits set
2. RMSDI - is the Running Mean of the 10 previous SDIs (if fewer than 10 results on file, "Too Few" is printed).
3. RM %DEV - Average of the last 10 %DEV for this parameter.
4. RMTS - Average of the last 10 Target Scores for this parameter.
5. All poor performance is highlighted in bold and underlined.
6. Overall RMSDI = average RMSDI for this sample distribution.
7. Overall RM%DEV = average RM%DEV for this sample distribution.
8. Overall RMTS = average RMTS for this sample distribution.

END-OF-CYCLE QUANTITATIVE REPORT

The End-of-Cycle Report is sent to labs receiving standard reports at the end of each cycle and provides a complete summary of statistics. Results can also be compared to the previous cycle.

Albumin, g/l

Method: Bromocresol Purple
Instrument: Siemens/Dade Dimension RxL/Max/Xpand
Reagent: Siemens/Dade Behring

RIQAS TDPA: 7.1% **Biological Variation:** 3.9%

Sample	Result	Unit	N	Mean for Comparison	CV%	Um	SDPA	SDI	TS	%Deviation
1	28.200	g/l	68	I 28.013	2.4	0.10	1.26	0.15	120	0.67
2	26.900	g/l	87	I 26.853	2.7	0.10	1.21	0.04	120	0.17
3	39.900	g/l	71	I 40.531	2.5	0.15	1.82	-0.35	118	-1.56
4	19.200	g/l	81	I 19.429	2.5	0.07	0.87	-0.26	120	-1.18
5	41.700	g/l	67	I 41.859	2.0	0.13	1.88	-0.08	120	-0.38
6	57.300	g/l	87	I 57.257	2.7	0.21	2.58	0.02	120	0.08
7	45.000	g/l	72	I 45.850	2.1	0.14	2.06	-0.41	110	-1.85
8	27.600	g/l	87	I 28.013	2.5	0.09	1.26	-0.33	120	-1.47
9	41.200	g/l	70	I 41.891	2.2	0.14	1.88	-0.37	115	-1.65
10	26.900	g/l	83	I 26.742	3.3	0.12	1.20	0.13	120	0.59
11	40.700	g/l	71	I 40.601	2.2	0.14	1.83	0.05	120	0.24
12	45.100	g/l	80	I 45.456	2.2	0.14	2.04	-0.17	120	-0.78
13	27.300	g/l	63	I 28.179	2.0	0.09	1.27	-0.69	87	-3.12

	Cycle 45	Cycle 46
Cycle Average SDI	-0.23	-0.18
Cycle Average TS	110	116
Cycle Average %DEV	-1.05	-0.79
Cycle Average Absolute SDI	0.36	0.24
Cycle Average Absolute %DEV	1.63	1.06









END-OF-CYCLE REPORT TEXT SECTION

The text section summarises the statistical information for all samples.

1 **Albumin, g/l**

2 **Method:** Bromocresol Purple
Instrument: Siemens/Dade Dimension RxL/Max/Xpand
Reagent: Siemens/Dade Behring

3 **RIQAS TDPA:** 7.1% **Biological Variation:** 3.9%

Your assay details at the end of the cycle. The RIQAS TDPA and biological variation for the parameter are shown if available.

4 Sample	5 Result	6 Unit	7 N	8 Mean	9 SDPA	10 Um	11 CV%	12 SDI	13 TS	14 % Deviation
1	28.200	g/l	68	I 28.013	1.26	0.10	2.4	0.15	120	0.7
2	26.900	g/l	87	I 26.853	1.21	0.10	2.7	0.04	120	0.2
3	39.900	g/l	71	M 40.531	1.82	0.15	2.5	-0.36	116	-1.5
4	19.200	g/l	81	I 19.429	0.87	0.07	2.5	-0.27	120	-1.2
5	41.700	g/l	67	I 41.942	1.88	0.13	2.0	-0.09	120	-0.4
6	57.300	g/l	87	I 57.257	2.58	0.21	2.7	0.02	120	0.1
7	45.000	g/l	72	I 45.850	2.06	0.14	2.1	-0.43	108	-1.8
8	27.600	g/l	87	I 28.011	1.26	0.09	2.5	-0.34	118	-1.5
9	41.200	g/l	70	I 41.823	1.88	0.14	2.2	-0.38	113	-1.6
10	26.900	g/l	83	I 26.742	1.20	0.12	3.3	0.14	120	0.6
11	40.700	g/l	71	I 40.601	1.83	0.13	2.2	0.06	120	0.2
12	45.100	g/l	80	I 45.119	2.05	0.14	2.2	-0.18	120	-0.8
13	27.300	g/l	63	I 28.454	1.27	0.09	2.0	-0.72	86	-3.1

Summary of your results and statistics are shown, including Mean for Comparison, SDPA, %CV, U_m, SDI, Target Score, %Deviation.

	Cycle 45	Cycle 46
Cycle Average SDI	-0.23	-0.18
Cycle Average TS	110	116
Cycle Average %DEV	-1.05	-0.79
Cycle Average Absolute SDI	0.36	0.24
Cycle Average Absolute %DEV	1.63	1.06

15 16

Table containing a summary of your performance for previous cycle and current cycle, including Average Absolute SDIs and %Deviations.

END-OF-CYCLE REPORT TEXT SECTION

1. Report presented in your chosen unit
2. Your assay details as of the last sample
3. RIQAS TDPA and Biological variation
4. Sample number
5. Your results for each sample
6. Unit your result was returned in
7. Number of results used for statistical analysis
8. Mean for Comparison (including comparison level)
9. SDPA = Standard Deviation for performance assessment
10. Uncertainty of Mean for Comparison
11. Coefficient of Variation (%)
12. Your Standard Deviation Index
13. Your Target Score
14. Your %Deviation
15. Cycle average of your performance indicators – Standard Deviation Index, Target Score and %Deviation.

Cycle Average SDI =

$$\frac{\text{(Sum of SDIs returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

Cycle Average Target Score =

$$\frac{\text{(Sum of your Target Scores returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

Cycle Average %Deviation =

$$\frac{\text{(Sum of your \%Deviations returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

16. Cycle average for Absolute values of your SDI and %Deviation. Absolute values show how far a value is from zero regardless of the sign. This is an indication of the magnitude of accuracy.

Cycle Average Absolute SDI =

$$\frac{\text{(Sum of your Absolute SDIs returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

Cycle Average Absolute %Deviation =

$$\frac{\text{(Sum of your Absolute \%Deviations returned for the completed cycle)}}{\text{(Number of samples returned in cycle)}}$$

END-OF-CYCLE CHART SECTION REPORT

Your results for current cycle shown in various diagrams.



1	**Levey-Jennings chart**	Shows your SDIs for a full cycle. • Shows SDI (positive and negative) x Shows absolute SDI
2	**Target Score chart**	Shows your Target Scores for a full cycle.
3	**%Deviation by sample chart**	Shows your %Deviations for a full cycle. Acceptable limits equal to TDPA unless alternative limits are registered by the lab. • Shows %Deviation (positive and negative) x Shows absolute %Deviation
4	**%Deviation by Concentration chart**	Shows your results for a full cycle.

END-OF-CYCLE CURRENT & PREVIOUS CYCLE ABSOLUTE SDIs REPORT

Based on the cycle average absolute SDI, this chart provides a visual representation of your laboratory's performance compared to the previous cycle.



1	**Parameter list**	List of all parameters registered.
2	**Results for previous cycle**	Indicated by open circle on the chart.
3	**Report title - Cycle Average Absolute SDI**	This shows your performance this cycle compared to the previous cycle.
4	**Results for current cycle**	Indicated by a closed circle on the chart.
5	**Legend**	Cycle Average Absolute SDIs are shown for: **L** Your results throughout the cycle **C** All labs within your own country **W** All labs Worldwide
6	**Graphical representation of Absolute SDIs**	Acceptable performance is < 2. If Absolute SDI for current cycle is less than that for the previous cycle, this is indicated by a green circle. If Absolute SDI for current cycle is greater than that for the previous cycle, this is indicated by a red circle. The closer the circle is to zero, the better the performance.

END-OF-CYCLE CERTIFICATE OF PERFORMANCE REPORT

An End-of-Cycle report will be issued for all registrations. However, the Certificate of Performance will only be available for parameters where results for at least 50% of samples in the cycle have been returned. Labs joining after the beginning of the cycle will only receive the Certificate of Performance if they meet this criterion. Any parameters not included on the Certificate of Acceptable Performance will be listed on the Notification of Unacceptable Performance.

RIQAS RANDOX INTERNATIONAL QUALITY ASSESSMENT SCHEME

CERTIFICATE OF ACCEPTABLE PERFORMANCE

Laboratory Name (1)
Laboratory Address
Country

(2) **LABORATORY REF. NO. 111/A**

(3) **CLINICAL CHEMISTRY - CYCLE 66**

(4) **05/09/2022**

This is to certify that the above participant took part in a cycle of external quality assessment and achieved an acceptable level of performance (Cycle Average Absolute SDI < 2) for the following parameters:

(5)	(6) Cycle Average Absolute SDI
Albumin - Bromocresol Green - Abbott Alinity i	1.61
Alkaline Phosphatase - AMP optimised to IFCC - Abbott Alinity c	0.80
ALT (GPT) - Tris buffer without P5P - Abbott Alinity c	1.20
Amylase, Total - Other 2-chloro-pNPG3 - Abbott Alinity c	0.99
AST (GOT) - Tris buffer without P5P - Abbott Alinity c	0.50
Bile Acids - Enzymatic Colorimetric - Abbott Alinity c	0.49
Bilirubin, Direct - Diazo with Dichloroanaline - Abbott Alinity c	0.36
Bilirubin, Total - Diazo with Dichloroaniline - Abbott Alinity c	0.72
Calcium - Arsenazo - Abbott Alinity c	0.69
Chloride - ISE, direct - Abbott Alinity c	1.08
Cholesterol - Cholesterol Oxidase - Abell Kendall - Abbott Alinity c	0.63
CK, Total - Abbott CK-NAC (IFCC) - Abbott Alinity c	0.47
Creatinine - Alkaline picrate no deproteinisation - Abbott Alinity c	1.42
GGT - Gamma glut.-3-carb.-4-nitro. - Abbott Alinity c	0.83
Glucose - Hexokinase - Abbott Alinity c	0.75

1	**Full registration address**	Your full registration address details.
2	**Your lab reference number**	Used to identify each lab.
3	**Programme / cycle number**	Programme and current, completed cycle number.
4	**Date**	Date End-of-Cycle report is issued.
5	**Parameters**	List of parameters including the assay details for which cycle absolute SDI is < 2.
6	**Average Absolute SDI**	Your Cycle Average Absolute SDI.

MULTI-INSTRUMENT REPORT

Register up to five instruments per programme at no extra cost. In addition to a standard report for each instrument, a multi-instrument report is also provided allowing comparitive performance assessment.



Summary Multi-Instrument Report **Randox**

CLINICAL CHEMISTRY **Performance Summary: %Deviation** **Cycle: 53** **Sample: 3** **19/10/2022**

Alkaline Phosphatase

%Deviation Summary **Allowable %Deviation = 15.8%**

Participant Name	Registration Name	7	8	9	10	11	12	13	1	2	3	RM%DEV	Lab. Ref.
Lab A	Instrument 1	264.4	2.8	7.5	-2.1	0.6	-5.6	-0.6	0.8	8.9	-2.6	27.4	12338/B
Lab B	Instrument 2	-2.0	2.5	0.2	-1.1	-1.7	-0.2	1.1	-3.9	-1.2	-0.7	-0.7	237024/A
Lab B	Instrument 3	0.8	-1.7	4.3	1.7	-0.2	0.0	-1.0	-2.2	1.2	-0.2	0.3	237024/B
Lab C	Instrument 4	-5.4	-4.1	-0.7	3.4	2.8	0.1	-0.7	-0.8	-3.9	0.5	-0.9	86301/C
Lab C	Instrument 5	1.3	-5.2	-0.9	1.1	-6.1	-3.1	-0.4		-7.0	0.0	-1.5	86301/D

1. Allowable %deviation for the parameter in question, based on the RIQAS TDPA.
2. Sample number.
3. Lab name.
4. Unique instrument ID.
5. Poor performance.
6. %Deviation for each individual sample.
7. RM %Dev - Average of the last 10 %Dev for this parameter.
8. %Deviation chart comparing the performance of each instrument.

URINE TOXICOLOGY REPORT

Laboratory performance is presented in both quantitative and qualitative screening formats, allowing for easy interpretation at-a-glance.

Screening Section

Quantitative Section

Amphetamines Group, ng/ml

Your Result Positive

Based on comparison value of 750
and your chosen cut-off value of 500
the correct response was Positive



MDMA	750	ng/ml
Ethanol	62.5	mg/dl
EDDP	75	ng/ml
Free Morphine	1500	ng/ml
Nortriptyline	375	ng/ml

	Cut-off	TN	TP	FN	FP	RC	NT	Total
Your Result	**500**	**0**	**1**	**0**	**0**	**0**	**0**	**1**
KIMS	**500**	**0**	**21**	**0**	**0**	**0**	**0**	**21**
	1000	0	0	0	9	0	0	9
	All	0	21	0	9	0	0	30
All Methods	150	0	1	0	0	0	0	1
	300	0	5	9	0	0	0	14
	500	**0**	**32**	**49**	**0**	**0**	**0**	**81**
	1000	65	0	0	10	0	3	78
	All	65	38	58	10	0	3	174
Competitive Antibody Binding	**500**	**0**	**3**	**0**	**0**	**0**	**0**	**3**
CEDIA	**500**	**0**	**2**	**4**	**0**	**0**	**0**	**6**
DRI-EIA	**500**	**0**	**3**	**3**	**0**	**0**	**0**	**6**
ELISA	**500**	**0**	**0**	**1**	**0**	**0**	**0**	**1**
EMIT	**500**	**0**	**1**	**27**	**0**	**0**	**0**	**28**
EMIT II+	**500**	**0**	**0**	**8**	**0**	**0**	**0**	**8**
Point of Care	**500**	**0**	**0**	**5**	**0**	**0**	**0**	**5**
Quidel Triage	**500**	**0**	**2**	**1**	**0**	**0**	**0**	**3**

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	74	656.297	77.4	73.82	507.99	23
KIMS	25	1344.540	15.1	50.82	203.30	2

Your Result	1405.000	SDI	0.30
		RMSDI	-0.12
Mean for Comparison	1344.540		



Method	N	Mean	CV%	U_m
EMIT	15	135.267	19.2	8.37
KIMS	25	1344.540	15.1	50.82
DRI-EIA	10	511.420	5.6	11.22
EMIT II+	5	119.540	22.4	14.98
CEDIA	5	298.942	89.9	150.22
Competitive Antibody Binding	4	540.725	2.7	9.19
ELISA	3	501.033	4.9	17.73

Performance History

Your Data (Last 10 Samples)	Your Method (This Sample)	Your Method (Last 10 Samples)	All Methods (This Sample)	All Methods (Last 10 Samples)
0 % False Negatives	0 % False Negatives	1 % False Negatives	34 % False Negatives	11 % False Negatives
10 % False Positives	30 % False Positives	11 % False Positives	6 % False Positives	5 % False Positives
90 % Correct Responses	70 % Correct Responses	88 % Correct Responses	60 % Correct Responses	83 % Correct Responses

URINE TOXICOLOGY REPORT SCREENING SECTION

Qualitative comparison of screening results available for each parameter.





1. Text section shows the correct response for the lab based on a comparison between the comparison value and the lab's cut off value.
2. **Screening Results:** This chart is a quick visualisation of your performance over the last 20 samples. A result in the white section indicates a correct response. A result in the upper red section indicates a False Positive response, and a result in the lower red section indicates a False Negative response.
3. Comment section for RIQAS to provide your laboratory with additional relevant information regarding this sample, such as spiked metabolite concentration.
4. Screening result response categories. All abbreviations indicated at the bottom of the report page.
   Key
   TN - true negative **TP** - true positive **FN** - false negative
   FP - false positive **RC** - sent for confirmation **NT** - not tested
5. **Screening Summary:** Your screening result shown in the appropriate response category and your cut off for this sample.
6. Screening results for all cut-offs returned for this sample within your method group.
7. Total screening results over all cut-offs for your laboratory's method.
8. Screening results for all cut-offs returned for this sample over all methods.
9. Total screening results over all cut-offs for all methods.
10. Screening results for other methods using same cut-off as your laboratory.
11. Performance history for this parameter, based on previous 10 samples.
12. Performance of your method over all cut-offs for this sample.
13. Performance history of your method over all cut-offs, based on the previous 10 samples.
14. Performance of all methods over all cut-offs for this sample.
15. Performance history of all methods over all cut-offs, based on the previous 10 samples.

URINE TOXICOLOGY REPORT QUANTITATIVE SECTION

Quantitative statistical comparison available for each parameter.



1. **Quantitative Text Section:** Comparison statistics. Caution is needed when the N value is too small to support statistical significance.
2. Your Result.
3. Your Mean for Comparison.
4. **Standard Deviation Index** =
$$\frac{\text{(Your Result – Mean for Comparison)}}{\text{SD of Mean for comparison}}$$
5. Running mean SDI = average of last 10 SDIs for this parameter (If fewer than 10 results, "Too Few" is printed).
6. **Quantitative Results Histogram:** This graph provides a quick visualisation of how your quantitative result falls into the overall picture for all methods and your method group.
7. All available method statistics for this sample.

URINALYSIS REPORT

Your performance for each parameter is presented in a simple, convenient report.



1. Categories are stated in your unit.
2. Your method group.
3. Your categories (available result options for chosen test strip and unit).
4. All categories (result options) available for this parameter for any method (test strip).
5. Results from all methods (test strips) returning results in the same categories as your lab.
6. Your Result.
7. **Your Score:** Scores between 0-6 are acceptable, 7 borderline and 8 -10 unacceptable.
8. Target categories and percentages of submitted results in that categories. Target categories are based on 80% consensus in the results in your categories. Multiple categories may be used to make up the 80% consensus. Target categories are highlighted by * in text section.
9. Performance Statement.
10. **Historical Performance:** Provides number of correct scores and acceptable assessments for the last 6 samples.
11. **Categories Histogram:** A quick visualisation of how your lab's result falls into the overall picture for your categories.
12. Possible reporting categories for your method. Target categories are highlighted by *.
13. Your result is indicated by the black triangle.
14. **Levey-Jennings type chart:** Acceptable scores (0-6) have no shading, borderline scores (7) have light red shading, unacceptable scores (8-10) have dark red shading.
15. Score for each sample number.
16. Sample Number.
17. **Target Categories:** If there was more than 1 target category assigned for a sample Multi is stated.
18. All methods reported for this parameter.
19. **Detailed summary of results:** This table enables you to see how you compare to all other results.

SEROLOGY REPORT

Laboratory performance is presented in both quantitative and qualitative screening formats, allowing for easy interpretation at-a-glance.

Anti-Rubella IgG, IU/ml

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	268	49.505	50.3	1.90	24.90	19
Abbott Architect/ Alinity	86	29.416	5.2	0.21	1.53	10

Your Result	27.800	SDI	-1.06
Your Qualitative Result	Reactive	RMSDI	0.00
Mean for Comparison	29.416		

Your method:	Abbott Architect/ Alinity
Your result:	Reactive
Acceptable result (Method):	Reactive

Overall results

Non-Reactive:	2
Inconclusive:	0
Reactive:	278







Method	N	Non-Reactive	Inconclusive	Reactive
Abbott Architect/ Alinity	94	0	0	94
Roche Cobas e601/ 602	41	0	0	41
BioMerieux VIDAS	25	0	0	25
Roche Cobas 4000/e411	22	0	0	22
Roche Cobas e402/e801	21	0	0	21
DiaSorin Liaison XL	14	0	0	14
Siemens Atellica IM	10	0	0	10
Siemens/DPC Immulite 2000/2500	9	0	0	9
Ortho Vitros 3600/5600/ECi/XT 7600	9	1	0	8
Beckman Dxl 600/800	6	0	0	6
DiaSorin, Liaison	6	1	0	5
Siemens Centaur XP/XPT	5	0	0	5
Siemens Centaur XP/XPT RbGII	5	0	0	5
SNIBE Maglumi analysers	4	0	0	4
Siemens Atellica IM RbGII	3	0	0	3

Method	N	Mean	CV%	U_m
Abbott Architect/ Alinity	86	29.416	5.2	0.21
Roche Cobas e601/ 602	38	82.481	5.8	0.97
BioMerieux VIDAS	25	46.540	7.7	0.89
Roche Cobas 4000/e411	22	81.417	7.1	1.54
Roche Cobas e402/e801	21	92.786	5.0	1.26
DiaSorin Liaison XL	15	33.353	8.4	0.90
Siemens Atellica IM	9	225.947	10.8	10.19
Siemens/DPC Immulite 2000/2500	9	35.522	9.8	1.45
Ortho Vitros 3600/5600/ECi/XT 7600	8	49.850	14.4	3.18
Beckman Dxl 600/800	7	37.774	14.0	2.49
DiaSorin, Liaison	5	35.180	5.9	1.17
Siemens Centaur XP/XPT	3	283.233	12.0	24.50
Siemens Centaur XP/XPT RbGII	5	33.846	8.0	1.50
SNIBE Maglumi analysers	4	10.088	4.2	0.27
Siemens Atellica IM RbGII	3	34.117	3.5	0.87

SEROLOGY: QUALITATIVE REPORT

Your performance for each sample is presented in a convenient single page per parameter report format.

Anti-Rubella IgG, IU/ml

Your method:	Abbott Architect/ Alinity
Your result:	Reactive
Acceptable result (Method):	Reactive

Overall results

Non-Reactive:	2
Inconclusive:	0
Reactive:	278



Method	N	Non-Reactive	Inconclusive	Reactive
Abbott Architect/ Alinity	94	0	0	94
Roche Cobas e601/ 602	41	0	0	41
BioMerieux VIDAS	25	0	0	25
Roche Cobas 4000/e411	22	0	0	22
Roche Cobas e402/e801	21	0	0	21
DiaSorin Liaison XL	14	0	0	14
Siemens Atellica IM	10	0	0	10
Siemens/DPC Immulite 2000/2500	9	0	0	9
Ortho Vitros 3600/5600/ECi/XT 7600	9	1	0	8
Beckman Dxl 600/800	6	0	0	6
DiaSorin, Liaison	6	1	0	5
Siemens Centaur XP/XPT	5	0	0	5
Siemens Centaur XP/XPT RbGII	5	0	0	5
SNIBE Maglumi analysers	4	0	0	4
Siemens Atellica IM RbGII	3	0	0	3

1. Your qualitative result and chosen method are presented along with the acceptable result based on an 80% consensus. This consensus will be at the method level if there are >=5 labs in the group or if there are <5 labs, will be at the all method level.
2. Overall Summary shows the number of results for this parameter and sample which are non-reactive, inconclusive or reactive.
3. Your Result is shown as a black triangle on the category chart compared to other laboratories in groups:

   All Methods ☐ Your Method ■
4. Summary shows performance of all the methods used to analyse the parameter.

SEROLOGY: SCREENING (QUANTITATIVE) REPORT

Your performance for each sample is presented in a convenient single page per parameter report format.



1 Quantitative statistics for All Methods and Your Method are presented in your chosen unit along with your result and your performance scores (SDI and RMSDI).

2 **Levey-Jennings chart** - Your SDIs for previous 20 samples.

3 Your result is presented on the bar graph as a black triangle, showing how you compare to:

All Methods **Your Method**

4 Multi Method Statistics section provides an easy way of assessing the performance of the methods used to analyse the parameter.

SERUM INDICES: SUMMARY PAGE

The RIQAS Serum Indices EQA programme is designed for the pre-analytical assessment of Haemolytic, Icteric and Lipemic (HIL) interferences. HIL parameters include the option of quantitative or semi-quantitative reporting. Interpretation of chemistry parameter results is also included for a number of parameters. The summary page collates the key information on both the quantitative and qualitative results for the HIL parameters.



Sample 1 - Normal
Sample 2 - Haemolytic
Sample 3 - Lipaemic

Sample	Analyte	Mean for Comparison	Your Result	SDI	%DEV
1	Haemolytic Index	13.750	14.000	0.02	1.8
	Icteric Index	0.980	1.100	0.17	12.2
	Lipaemic Index	13.600	8.000	-0.83	-41.2
2	Haemolytic Index	469.000	500.000	0.34	6.6
	Icteric Index	2.475	<2.500		
	Lipaemic Index	40.000	45.000	1.23	12.5
3	Haemolytic Index	53.000	<50.000		
	Icteric Index	5.700	6.100	0.28	7.0
	Lipaemic Index	42.000	<40.000		

Sample	Analyte	Target Categories	Your Result	Your Score
1	Haemolytic Index	0	0	0
	Icteric Index	0	0	0
	Lipaemic Index	0	0	0
2	Haemolytic Index	4+ 5+	5+	0
	Icteric Index	0	0	0
	Lipaemic Index	0	1+	1
3	Haemolytic Index	0	0	0
	Icteric Index	2+	2+	0
	Lipaemic Index	0	0	0

1. The first section shows the status of each of the samples i.e. if the sample is a normal sample or if it is haemolytic, icteric or lipaemic.
2. The next section shows the summary of the quantitative results for the Serum Indices and your performance (SDI and %DEV) for each sample.
3. The final section shows the summary of the semi-quantitative results for the Serum Indices. This includes the target categories based off an 80% consensus in the results, your result and your score for each of the samples.

SERUM INDICES REPORT

The summary section is followed by report pages for the 3 serum indices parameters. There will be 3 pages for each index – one for each sample.

Quantitative Section

Semi-quantitative Section



Icteric Index, mg/dl

1 **Sample 18 Icteric**

	N	Mean	CV%	U_m	SDPA	Exc.
All Methods	77	11.036	7.5	0.12	0.82	7
Abbott Alinity	17	11.978	4.2	0.15	0.52a	1
Abbott Alinity c	17	11.978	4.2	0.15	0.52a	1

Your Result	11.800	SDI	-0.34
Mean for Comparison	11.978	%DEV	-1.5

	0	1+	2+	3+	4+	5+	6+	7+
All Methods	2	1	7	18	1	0	1	0
IIAAC *	0	0	0	9	0	0	0	0

Your Result 3+ Your Score 0

Target Categories 3+

* IIAAC = Abbott Alinity

Number of Laboratories

< 9.18 10.41 11.65 12.88 >

mg/dl

Mean for Comparison

Number of Laboratories

0 1+ 2+ 3+ 4+ 5+ 6+ 7+

Categories

Standard Deviation

Sample Number

Variation from Target

Sample Number

1 Under the Serum Index parameter name the report will display the sample status e.g. if the sample should be flagging as haemolytic, icteric or lipaemic. As with all reports, the results contained within the report pages will be in the unit selected by the lab during the registration process.

SERUM INDICES REPORT: QUANTITATIVE SECTION

Quantitative comparison of results available for each index.



1 **Text Section:** In the text section you will see the All method, method and instrument means for comparison in addition to the respective statistics. Below this you will see your result, your Mean for comparison and your performance (SDI and %DEV) for this specific sample. For samples which do not hit specific flags for the indices, a large proportion of analysers will have a less than (<) setting. On a RIQAS report these will be counted in the excluded column. As one sample in each distribution will be a normal sample, it is likely there will be a large number of (<) results returned for these samples so we are indicating in this section the percentage of results that have been returned as a < or > result to allow labs to see if the number of excluded results is high that there is an explanation for this.

2 **Histogram:** As with other RIQAS reports, this histogram shows an overview of the spread of the results that have been returned for each level of comparison (all method (white), method (green) and instrument (blue)). The lab's result is indicated by the black triangle at the bottom of the chart.

3 **Levey Jennings style chart:** The Levey Jennings chart will display the lab's SDIs. These reflect laboratory performance in relation to SDPAs and are useful to monitor performance over time. Acceptable performance is SDI < 2. The sample numbers will be displayed along the bottom of the chart and the Means for Comparison including the level will be displayed along the top of the report.

SERUM INDICES REPORT: SEMI-QUANTITATIVE SECTION

Semi-quantitative comparison of the results available for each parameter.



1 **Text Section:** This shows the breakdown of the semi-quantitative results returned – broken down by all methods and the labs chosen method. The method is displayed as a code, the description for which is found in the box just below containing the lab's result.

The lab's result, target categories (based on an 80% consensus), and the lab's score based on how many categories away from the target category the result is, are displayed below the breakdown of each category.

2 **Histogram:** The histogram shows a pictorial breakdown of the results returned for each category. The lab's result is indicated by the black triangle at the bottom of the chart.

3 **Levey Jennings chart:** This chart will display the lab's score or variation from the target category.

The sample numbers will be displayed along the bottom of the chart and the target categories along the top. If there is more than one target category, the chart will display the word 'Multi'.

SERUM INDICES REPORT: CHEMISTRY PARAMETER PAGE

Following the report pages for the 3 Serum Indices, there are the report pages for any chemistry parameters labs have registered for. There are 2 pages for each parameter, one showing the comparison between the first sample (the normal sample) and the second sample and the second page showing the comparison between the first and third sample respectively.



1 **Sample Status:** Under the chemistry parameter name the report will display the sample status e.g. if the sample should be flagging as haemolytic, icteric or lipaemic for the 2 samples being compared. As with all reports, the results contained within the report pages will be in the unit selected by the lab during the registration process.

The rest of the report page shows the same information for each of the 2 samples being compared.

The first sample of the 3 in each distribution will be the normal sample, the other 2 may or may not flag for one or more of the Indices.

2 **Text Section:** In the text section you will see the all method, method and instrument means for comparison and the respective statistics. Below this you will see you result, your Mean for comparison and your performance (SDI and %DEV) for this specific sample.

The % shift in the Means for Comparison between the normal and the affected sample is displayed in the results box for the second and third sample.

3 **Histogram:** As with other RIQAS reports, this histogram shows an overview of the spread of the results that have been returned for each level of comparison (all method (white), method (green) and instrument (blue)). The lab's result is indicated by the black triangle at the bottom of the chart.

4 **Method Summary Section:** As with other RIQAS reports, this section provides an easy way of assessing the performance of other methods used to analyse the parameter in question. The code at the beginning of the description is the key to the following section - Reporting of the Result based on Serum Indices flag.

5 **Reporting of the Result based on Serum Indices flag:** Depending on the Index that has been flagged, the lab may choose to not report the result to the clinician. In this section the lab can report on whether they would report the result for this parameter based on the result from the Serum Indices analysis.

BACTERIAL IDENTIFICATION REPORT

Presented in a convenient single report, all results for the current sample will be displayed within 6 sections.

Number of expected organisms in this sample: 1

Expected Organism: Pseudomonas aeruginosa

Your Result for this Organism: Pseudomonas aeruginosa

Result sent for referral (as per laboratory protocol)? No

Case study - A 41 year old fireman was badly burned during a house fire. This organism was cultured from his subsequently infected wound.

Current Performance

Your Score for this Organism: 3

	Correct Assessment (N)	Score Averages Overall	Your Method
Global	125	2.84	2.76
Country	22	2.95	2.92

Organisms Reported

Expected Organism: Pseudomonas aeruginosa



Methods in Use



Method	Incorrect	Partial	Correct
All Methods	3	6	125
Conventional tests	3 (3.3)	6 (6.7)	81 (90.0)
VITEK 2 (all models)	0 (0.0)	0 (0.0)	32 (100.0)
BD Phoenix (all models)	0 (0.0)	0 (0.0)	6 (100.0)
MicroScan WalkAway	0 (0.0)	0 (0.0)	3 (100.0)
Sensititre Aris 2X	0 (0.0)	0 (0.0)	3 (100.0)

BACTERIAL IDENTIFICATION REPORT

Participants can quickly and easily identify their performance for the current sample against their peers across geographic locations and those utilising same methodologies. Each section is explained in further detail below.



Number of expected organisms in this sample: 1

1

Expected Organism: Pseudomonas aeruginosa

Your Result for this Organism: Pseudomonas aeruginosa

Result sent for referral (as per laboratory protocol)? No

Case study - A 41 year old fireman was badly burned during a house fire. This organism was cultured from his subsequently infected wound.

2

Current Performance

Your Score for this Organism: 3

	Correct Assessment (N)	Score Averages	
		Overall	Your Method
Global	125	2.84	2.76
Country	22	2.95	2.92

3

1 **Sample Results:** This shows the expected organism, the labs selected organism and information on the laboratory protocol being followed. Information on the lab's protocol will have an effect on the scoring for this sample.

2 **Case Study:** Clinical details are provided for each sample.

3 **Performance Scoring:** This will contain the lab's specific score for this sample. It will also show the correct assessments and overall scoring with the lab's country and globally.

If sample is NOT sent for referral, scoring is marked out of 3
- Correct Genus + species = 3
- Correct Genus + species is blank, if this is lab protocol = 3
- Correct Genus + species is blank = 1
- Correct Genus + incorrect species = 1
- Incorrect Genus and species but correct Gram stain = 0
- Incorrect Genus, species and Gram stain = -1

If sample is sent for referral, scoring is marked out of 2
- Correct Genus + species = 2
- Correct Genus + species is blank, if this is lab protocol = 2
- Correct Genus + species is blank = 1
- Correct Genus + incorrect species = 1
- Incorrect Genus and species but correct Gram stain = 0
- Incorrect Genus, species and Gram stain = 0

BACTERIAL IDENTIFICATION REPORT



4

Bar Chart of Organisms Reported: This will list all organisms reported by each lab ordered in descending frequency. The black triangle indicates the lab's result.

5

Bar Chart Detailing Methods Used: This will list all methods used by each lab ordered in descending frequency. The bars are colour coded to highlight correct, partial and incorrect responses for each method. The black triangle indicates the lab's result.

6

Method Summary Section: This is a table providing the number of responses by method. The figures in brackets indicate the percentage of responses for each method.

BACTERIAL IDENTIFICATION - HISTORICAL PERFORMANCE

Track your performance across the previous 12 specimens using this one-page report.



1. This shows the lab's score across the last 6 samples. This score is also shown as a percentage.
2. This shows the percentages for the lab's country and globally for the last 6 samples. This is broken down by the lab's method and all methods.
3. A chart showing the lab's historical performance score. The expected organism for each sample is displayed along the top of the chart.
4. A chart showing the percentages for the lab, their country and globally. Each plot is the percentage score for 6 rolling samples.

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Antimicrobial susceptability testing table details all reported antibiotics for current sample and AST response.

Antimicrobial Susceptibility Testing

Organism: Pseudomonas aeruginosa

Antibiotic	Resistant	Intermediate	Sensitive	Your Result (Score)	Target
Amikacin	2	2	107	Sensitive (2/2)	**Sensitive (Y)**
Amoxicillin	2	0	0		Too Few
Amoxicillin/Clavulinic Acid	2	0	0		Too Few
Ampicillin	6	0	1		**Resistant (A)**
Ampicillin/Sulbactam	1	0	1		Too Few
Azithromycin	0	1	0		Too Few
Aztreonam	1	9	15	Intermediate (N/A)	N/A
Cefazolin	3	1	0		Too Few
Cefepime	2	25	68	Intermediate (2/2)	**Intermediate (Y)**
Cefixime	2	0	0		Too Few
Cefodime	0	2	3		Too Few
Cefoperazone	0	0	1		Too Few
Cefoperazone/Sulbactam	0	0	1		Too Few
Cefotaxime	8	0	0		**Resistant (A)**
Cefoxitin	1	0	1		Too Few
Cefpodoxime	1	0	1		Too Few
Ceftazidime	1	29	80	Intermediate (1/2)	**Sensitive (A)**
Ceftazidime/Avibactam	0	0	5		**Sensitive (A)**
Ceftolozane/Tazobactam	0	1	6		**Sensitive (A)**
Ceftriaxone	2	0	0		Too Few
Cefuroxime	3	0	0		Too Few
Ciprofloxacin	0	33	85	Intermediate (2/2)	**Intermediate (Y)**
Clindamycin	0	0	1		Too Few
Colistin	1	6	17		**Sensitive (Y)**
Cotrimoxazole	1	0	0		Too Few
Doripenem	0	0	6		**Sensitive (A)**
Doxycycline	1	0	0		Too Few
Ertapenem	2	0	0		Too Few
Erythromycin	0	0	1		Too Few
Fosfomycin	4	0	0		Too Few
Gentamicin	6	5	80	Sensitive (2/2)	**Sensitive (Y)**
Imipenem	13	27	57	Intermediate (2/2)	**Intermediate (Y)**
Levofloxacin	3	15	25	Intermediate (N/A)	N/A

- Target based on 80% agreement or at least 30% more than next common response
- Target requires at least 5 responses or else 'Too Few' is recorded
- Target is based initially on lab's guideline (Y) followed by all guidelines (A) if lab's guideline does not fulfil criteria. If neither of these are met then target recorded as N/A
- Participant responses are recorded for each antibiotic
- Participant responses from an incorrectly or partially identified organism are not included in totals

Scoring

- **If target is Sensitive**
  Response of sensitive = 2
  Response of intermediate = 1
  Response of resistant = 0
- **If target is Resistant**
  Response of sensitive = -1
  Response of intermediate = 1
  Response of resistant = 2
- **If target is Intermediate**
  Response of sensitive = 1
  Response of intermediate = 2
  Response of resistant = 1
- **No scoring possible if target is N/A or Too Few**

ANTIMICROBIAL SUSCEPTIBILITY TESTING

Antimicrobial susceptability testing table details all reported antibiotics for current sample and AST response.

Ticarcillin/Clauvulanic Acid	0	7	1	Intermediate (2/2)	**Intermediate (A)**
Tigecyclin	11	0	0		**Resistant (A)**
Tobramycin	1	0	53	Sensitive (2/2)	**Sensitive (Y)**
Trimethoprim/Sulfamethoxazole	6	2	1		N/A
Vancomycin	0	0	1		Too Few

1 Your Score	19 out of 20	95.0%
Your Guideline: EUCAST	350 out of 456	76.8%
All Guidelines	1755 out of 2048	85.7%

3 of your antibiotics have no target and are not scored

1 **Scoring Summary**

- A total score for the participants responses that had targets is provided for the participant

  Your Score

- A total score for all antibiotics that had targets is provided for

  Your Guideline
  All Guidelines

Cefepime

2 Guideline	Resistant	Intermediate	Sensitive	% Agreement
CLSI	0	0	31	100.0%
EUCAST	1	16	7	66.7%
Unspecified	1	9	30	75.0%

2 **Guideline Analsyis**

- For each antibiotic that has a target assigned, a breakdown of the responses per guideline is provided

MONITORING EQA PERFORMANCE

Each EQA report should be evaluated and any poor performance investigated. A step by step approach should be adopted consisting of the following three steps:

1. Investigate the source of the problem

In order to identify the source of the problem, it is useful to be aware of the most common causes of poor EQA performance. Errors can occur at any stage of the testing process; however, EQA is most concerned with detecting analytical errors i.e. errors that occur during the analysis of the sample.



Most analytical errors can be easily divided into three main areas; clerical errors, systematic errors and random errors. Systematic errors result in inaccurate results that consistently show a positive or negative bias. Random errors, on the other hand, affect precision and result in fluctuations in either direction.

It may be possible that, after extensive investigations, the root cause of the poor performance cannot be established. Poor performance for a single sample could be attributed to random error. If poor performance has been noted for several samples, a systematic error is the most likely cause and the analytical process should be reviewed.

Clerical errors
- Transcription errors
- Incorrect units used
- Incorrect sample tested
- Incorrect method classification
- Calculation/conversion error

Systematic errors
- Sample/Reagent prep/handling
- Reagent/calibrator/standardisation change
- Instrument/reagent/calibrator fault
- Inexperienced operators
- Reagent deterioration
- Inappropriate method

Random errors
- Bubbles in reagent
- Bubbles in reagent/sample pipette
- Temperature fluctuations
- Poor pipetting technique
- Poor operator technique

The flowchart (page 29) is designed to help you investigate any apparent poor performance.

2. Implement corrective actions

Some errors can be readily recognised as simple clerical errors and easily corrected. If there is evidence of systematic or random error however more detailed corrective actions must be taken.

Systematic Error

In the event of a systematic error, the following suggested actions may help to resolve the problem:

- Perform instrument maintenance
- Recalibrate instrument
- Review reagent/sample storage
- Check pipettes
- Prepare fresh reagents & re-run sample
- Perform staff training

Random Error

If all possible causes have been excluded, a single unacceptable result is most likely due to random error. Re-run the sample; if the result of repeat analysis is acceptable then corrective action is not required. If the issue persists, investigate possible sources of systematic error.

3. Check the effectiveness of corrective actions

The effectiveness or impact of any corrective actions taken can be assessed by continuing to monitor analytical performance over time.

MONITORING EQA PERFORMANCE

A checklist similar to the one below is extremely useful when investigating poor EQA performance and may help you to determine the root cause of the problem and initiate corrective actions.

Laboratory: .....

Cycle Number: ..... **Sample Number:** .....

Analysis Date: ..... **Analyte:** .....

Mean for Comparison: ..... **Lab Result:** ..... **SDI:** ..... **%Dev:** .....

1. Specimen Handling

a. Samples received in good condition (Y) (N)

b. Samples stored/prepared appropriately (Y) (N)

c. Integrity of the sample is acceptable (Y) (N)

2. Clerical

a. Correct result entered (Y) (N)

b. Correct use of decimal point and units (Y) (N)

c. Calculations, if any, performed correctly (even if automated) (Y) (N)

d. Conversion factors applied to results before submission (Y) (N)

3. Registration and Mean for Comparison

a. Registered in the correct method/instrument group (Y) (N)

b. Changed method or instrument without advising RIQAS (Y) (N)

c. Peer Group changed due to the number of participants returning results e.g. from method to instrument (Y) (N)

d. An obvious bias between method and instrument means (check histogram and stats sections) (Y) (N)

4. Internal Quality Control

a. %Deviation of IQC (at similar conc to that of EQA) on sample analysis date acceptable (Y) (N)

b. Shift in IQC in the periods just before and after EQA sample analysis (Y) (N)

c. Trends in IQC in the periods before and after EQA sample analysis (Y) (N)

d. Random IQC variation on sample analysis date (Y) (N)

e. Error due to imprecision; check IQC in terms of %Deviation compared to deviation observed in EQA (Y) (N)

f. IQC target correctly assigned (Y) (N)

5. Calibration

a. Date of last calibration ( )

b. Calibration frequency acceptable (Y) (N)

c. Last calibration acceptable (Y) (N)

6. Instrument

a. Daily maintenance performed on date of sample analysis (Y) (N)

b. Special maintenance performed prior to sample analysis (Y) (N)

c. Instrument operated correctly (Y) (N)

d. Operator fully trained (Y) (N)

7. Reagents

a. Reagents prepared and stored correctly (Y) (N)

b. Reagents within open vial stability (Y) (N)

8. EQA sample

a. Initial value ( )

b. Re-run value ( )

c. Issue observed in previous EQA samples at a similar concentration (check %Deviation by concentration and Levey Jennings charts) (Y) (N)

d. All parameters affected (to the same extent) - possible reconstitution error (check %Deviation on summary pages) (Y) (N)

Conclusion: .....

.....

.....

.....

Remedial Action: .....

.....

.....

.....

Lab Manager: ..... **Date:** .....

Lab Director: ..... **Date:** .....

MONITORING EQA PERFORMANCE

The flow chart below can be used to help identify a possible root cause for poor EQA performance.



RIQAS PROGRAMMES

Ammonia/Ethanol Programme *With target scoring*

RQ9164 (2 ml)
2 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Ammonia
Ethanol

Anti-Müllerian Hormone (AMH) Programme+

RQ9198 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

Anti-Müllerian Hormone (AMH)

Anti-TSH Receptor Programme+ *With target scoring*

RQ9174 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

Anti-TSH Receptor (TRAb)

Blood Gas Programme *With target scoring*

RQ9134 (1.8 ml)
First registered instrument
11 Parameters
RQ9134/A (1.8 ml)
Subsequent instruments
11 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Bicarbonate
Ca++
Cl-
CO_2(Total)
Glucose
Lactate
K+
Na+
pCO_2
pH
pO_2

BNP Programme+ *With target scoring*

RQ9165 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

BNP

Cardiac Programme *With target scoring*

RQ9127/a (1 ml)
2 Parameters only (choose from 7)
RQ9127/b (1 ml)
Full 7 Parameters
RQ9186 (1 ml)
Full 7 Parameters
Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription
Samples every month, 1 x 12 monthly cycle, 12 month subscription

CK, Total
CK-MB (Activity)
CK-MB (Mass)
Homocysteine
Myoglobin
Troponin I
Troponin T

Cardiac Plus Programme *With target scoring*

RQ9190 (3 ml)
11 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

CK, Total
CK-MB Activity
CK-MB Mass
D-dimer
Digoxin
Homocysteine
hsCRP
Myoglobin
NT proBNP
Troponin I
Troponin T

Cerebrospinal Fluid Programme+ *With target scoring*

RQ9168 (3 ml)
7 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Albumin
Chloride
Glucose
IgG
Lactate
Protein (Total)
Sodium

= Liquid ready-to-use samples = Lyophilised samples PURPLE = The only parameters available on RQ9135/a + = Not accredited * = Pilot study ongoing

RIQAS PROGRAMMES

Coagulation Programme *With target scoring*

RQ9135/a (1 ml)
5 Selected parameters only + 1 pilot
(aPTT, PT, TT, Fibrinogen, Antithrombin III)
Samples every month, 1 x 12 month cycle, 12 month subscription

RQ9135/b (1 ml)
Full 16 Parameters + 1 pilot

aPTT
PT (including INR)
TT
Fibrinogen
Antithrombin III
D-dimer*
Factor II
Factor V
Factor VII
Factor VIII
Factor IX
Factor X
Factor XI
Factor XII
Plasminogen
Protein C
Protein S

CO-Oximetry Programme+

RQ9177 (1.2 ml)
First registered instrument
7 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

RQ9177/A (1.2 ml)
Subsequent instruments
7 Parameters

Carboxyhaemoglobin (COHb / HbCO)
Deoxyhaemoglobin (HHb)
Methaemoglobin (MetHb)
Oxygen Content (O2CT)
Oxygen Saturation (sO2 / Vol O2)
Oxyhaemoglobin (O2Hb / HbO2)
Total Haemoglobin (tHb)

CYFRA 21-1 Programme+

RQ9175 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription

CYFRA 21-1 (Cytokeratin 19)

Cytokines Programme+

RQ9195 (1 ml)
1 Parameter + 11 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription

Epidermal Growth Factor (EGF)*
Interleukin – 1 alpha (IL-1α)*
Interleukin – 1 beta (IL-1β)*
Interleukin – 2 (IL-2)*
Interleukin – 4 (IL-4)*
Interleukin – 6 (IL-6)
Interleukin – 8 (IL-8)*
Interleukin – 10 (IL-10)*
Interferon gamma (INF-Y)*
Monocyte Chemoattractant Protein -1 (MCP-1)*
Tumour Necrosis Factor alpha (TNF-α)*
Vascular Endothelial Growth Factor (VEGF)*

ESR Programme+

RQ9163 (4.5 ml)
1 Parameter
2 samples per quarterly distribution, 1 x 12 month cycle, 12 month subcription

ESR (Erythrocyte Sedimentation Rate)

General Clinical Chemistry Programme *With target scoring*

RQ9112/a (5 ml)
10 Parameters

RQ9112/b (5 ml)
17 Parameters

RQ9112/c (5 ml)
Full 56 Parameters

RQ9128 (5ml)
Full 56 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription, reference method values

Samples every month, 1 x 12 monthly cycle, 12 month subscription

ACE (Angiotensin Converting Enzyme)
Acid Phosphatase (Prostatic)
Acid Phosphatase (Total)
Albumin
Alkaline Phosphatase
ALT (ALAT)
Amylase (Pancreatic)
Amylase (Total)
AST (ASAT)
Bicarbonate
Bile Acids
Bilirubin (Direct)
Bilirubin (Total)
Calcium
Calcium, Adjusted
Calcium (Ionised)
Chloride
Cholesterol
Cholinesterase
CK, Total (CPK)
Copper
Creatinine
D-3-Hydroxybutyrate
eGFR (estimated glomerular filtration rate)
Fructosamine
γGT
GLDH
Glucose
HBDH
HDL-Cholesterol
Iron
Lactate
LD (LDH)
LDL-Cholesterol
Lipase
Lithium
Magnesium
NEFA
Non-HDL Cholesterol
Osmolality
Phosphate (Inorganic)
Potassium
Protein (Total)
PSA
Sodium
TIBC
T_3 (Free)
T_3 (Total)
T_4 (Free)
T_4 (Total)
Triglycerides
TSH
UIBC
Urea
Uric Acid
Zinc

Glycated Haemoglobin Programme (HbA1c) *With target scoring*

RQ9129 (0.5ml)
2 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

HbA1c
Total Haemoglobin

= Liquid ready-to-use samples = Lyophilised samples PURPLE = The only parameters available on RQ9135/a + = Not accredited * = Pilot study ongoing

RIQAS PROGRAMMES

Haematology Programme *With target scoring*

RQ9118 (2 ml)
11 Parameters
Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

RQ9140 (2ml)
11 Parameters
Samples every month, 1 x 12 monthly cycle, 12 month subscription

Haematocrit (HCT)
Haemoglobin (Hb)
Mean Cell Haemoglobin (MCH)
Mean Cell Haemoglobin Concentration (MCHC)
Mean Cell Volume (MCV)
Mean Platelet Volume (MPV)
Platelets (PLT)
Plateletcrit (PCT)
Red Blood Cell Count (RBC)
Red Cell Distribution Width (RDW)
Total White Blood Cell Count (WBC)

Human Urine Programme *With target scoring*

RQ9115 (2 x 10 ml)
25 Parameters
Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

RQ9185 (10ml)
25 Parameters
Samples every month, 1 x 12 monthly cycle, 12 month subscription

ACR
Albumin/Microalbumin
Amylase
Calcium
Chloride
Copper
Cortisol
Creatinine
Dopamine
Epinephrine
Glucose
Metanephrine
Norepinephrine
Normetanephrine
Magnesium
Osmolality
Oxalate
Phosphate (Inorganic)
Potassium
Protein (Total)
Sodium
Urea
Uric Acid
VMA
5-HIAA

Immunoassay Programme *With target scoring*

RQ9125/a (5 ml)
4 Parameters only + 2 pilots

RQ9125/b (5 ml)
13 Parameters only + 2 pilots

RQ9125/c (5 ml)
Full 49 Parameters + 2 pilots

Samples every two weeks, 2 x 6 monthly cycles, 12 month subscription (RQ9125/a, RQ9125/b, RQ9125/c)

RQ9130 (5 ml)
Full 49 Parameters + 2 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription RQ9130)

ACTH
AFP
Aldosterone
Amikacin
Androstenedione
β-2-Microglobulin
CA125
CA15-3
CA19-9
Carbamazepine
CEA
Cortisol
C-Peptide
DHEA-Sulphate
DHEA Unconjugated
Digoxin
Ferritin
Folate
FSH
Gentamicin
GH
hCG
IgE
Insulin
LH
Oestradiol
17-OH-Progesterone
Paracetamol
Phenobarbital
Phenytoin
Progesterone
Prolactin
PSA (Free)
PSA (Total)
PTH
Salicylate
SHBG
T_3 (Free)
T_3 (Total)
T_4 (Free)
T_4 (Total)
Testosterone (Free)*
Testosterone (Total)
Theophylline
Thyroglobulin
TSH
Valproic Acid
Vancomycin
Vitamin B12
1-25-$(OH)_2$-Vitamin D*
25-OH-Vitamin D

Immunoassay Speciality 1 Programme *With target scoring*

RQ9141 (2 ml)
9 Parameters + 1 pilot
Samples every month, 1 x 12 month cycle, 12 month subscription

1-25-$(OH)_2$-Vitamin D*
25-OH-Vitamin D
C-Peptide
Anti-TG
Anti-TPO
IGF-1
Osteocalcin
Procalcitonin
PTH
Insulin

Immunoassay Speciality 2 Programme *With target scoring*

RQ9142 (1 ml)
5 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Calcitonin
Gastrin
Procalcitonin
Plasma Renin Activity
Renin (Direct Concentration)

Immunosuppressant Programme+

RQ9159 (2 ml)
4 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription, reference method values

Ciclosporin
Everolimus
Sirolimus
Tacrolimus

Lipid Programme *With target scoring*

RQ9126/a (3 ml)
3 Parameters only (choose from 7)

RQ9126/b (3 ml)
Full 7 Parameters

Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

Apolipoprotein A1
Apolipoprotein B
Cholesterol (Total)
HDL-Cholesterol
LDL-Cholesterol
Lipoprotein (a)
Triglycerides

= Liquid ready-to-use samples = Lyophilised samples PURPLE = The only parameters available on RQ9135/a + = Not accredited * = Pilot study ongoing

RIQAS PROGRAMMES

Maternal Screening Programme *With target scoring*

RQ9137 (1 ml)
6 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

AFP
free β-hCG
Total hCG
Inhibin A
PAPP-A
Unconjugated Oestriol

Microbiology (Bacterial Identification) Programme+

RQ9197
1 strain (complete with case study)
Samples every 2 months, 1 x 12 month cycles, 12 month subscription

1 strain complete with case study. Identification of the micro-organisms can be made at Gram positive / negative, Genus and Species level. Antimicrobial Susceptibility Testing on identified strain

Antimicrobial Susceptibility Testing
Strain Identification

Neonatal Bilirubin Programme+

RQ9191 (3 ml)
2 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Direct Bilirubin
Total Bilirubin

Psychiatric Drugs Programme

Serology (Anti-SARS-CoV-2) Programme+

RQ9193 (0.5 ml)
3 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

IgG
IgM
Total Antibodies

Serology (EBV) Programme+

RQ9153 (1 ml)
3 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-EBV VCA IgG
Anti-EBNA IgG
Anti-EBV VCA IgM

Serology (HIV-Hepatitis) Programme+

RQ9151 (1.8 ml)
10 Parameters + 6 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-CMV (Total)
Anti-HAV IgM*
Anti-HAV (Total)*
Anti-HBc
Anti-HBc IgM*
Anti-HBe (Total)*
Anti-HBs (Total)*
Anti-HCV
Anti-HIV-1
Anti-HIV-2
Anti-HIV combined
Anti-HTLV I
Anti-HTLV II
Anti-HTLV combined
HBsAg
P24*

Serology (Syphilis) Programme+

RQ9154 (1 ml)
1 Parameter
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Syphilis (Methods available include immunoassay RPR, VDRL and TPHA)

Serology (ToRCH) Programme+

RQ9152 (1 ml)
12 Parameters + 3 pilots
Samples every month, 1 x 12 month cycle, 12 month subscription, Quantitative and Qualitative results

Anti-CMV IgG
Anti-CMV IgM
Anti-HSV1 IgG
Anti-HSV1 IgM
Anti-HSV2 IgG
Anti-HSV2 IgM
Anti-HSV1/2 IgG
Anti-HSV1/2 IgM
Anti-Measles IgG*
Anti-Mumps IgG*
Anti-Rubella IgG
Anti-Rubella IgM
Anti-Toxoplasma IgG
Anti-Toxoplasma IgM
Anti-VZV IgG*

= Liquid ready-to-use samples = Lyophilised samples PURPLE = The only parameters available on RQ9135/a + = Not accredited * = Pilot study ongoing

RIQAS PROGRAMMES

Serum Indices Programme+

RQ9194 (1 ml)
3 Indices Assessments
25 Chemistry Parameters
Samples Bi-Monthly, 2 x 9 samples, 12 month subscription

RQ9194/A (1 ml)

Indices Assessment (Quantitative and Semi-Quantitative)

Haemolysis
Icteric
Lipaemic

Parameter Assessment (Quantitative)

ALP
ALT
AST
Bilirubin (Direct)
Bilirubin (Total)
Calcium
Chloride
Cholesterol
CK NAC
Creatinine
GGT
Glucose
HDL
Iron
Lactate
LDH
Lipase
Magnesium
Phosphate
Potassium
Protein (Total)
Sodium
Triglycerides
Urea
Uric Acid

Specific Proteins Programme *With target scoring*

RQ9114 (3 ml)
26 Parameters
Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription

RQ9187 (1ml)
26 Parameters
Samples every month, 1 x 12 monthly cycle, 12 month subscription

AFP
Albumin
α-1-Acid glycoprotein
α-1-Antitrypsin
α-2-Macroglobulin
Anti Streptolysin O
Antithrombin III
β-2-Microglobulin
Ceruloplasmin
Complement C_3
Complement C_4
C-Reactive Protein
Ferritin
Haptoglobin
IgA
IgE
IgG
IgM
Kappa Light Chain (Free)
Kappa Light Chain (Total)
Lambda Light Chain (Free)
Lambda Light Chain (Total)
Prealbumin (Transthyretin)
Retinol Binding Protein
Rheumatoid Factor
Transferrin

Sweat Testing Programme+

RQ9173 (2 ml)
2 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Chloride
Conductivity

Therapeutic Drugs Programme *With target scoring*

RQ9111 (5 ml)
18 Parameters
Samples every 2 weeks, 2 x 6 monthly cycles, 12 month subscription, Weighed-in values

Amikacin
Caffeine
Carbamazepine
Ciclosporin
Digoxin
Ethosuximide
Gentamicin
Lithium
Methotrexate
Paracetamol (Acetaminophen)
Phenobarbital
Phenytoin
Primidone
Salicylic Acid
Theophylline
Tobramycin
Valproic Acid
Vancomycin

Urinalysis Programme *With scoring*

RQ9138 (12 ml)
14 Parameters
Samples every 2 months, 1 x 12 month cycle, 12 month subscription

Albumin
Bilirubin
Blood
Creatinine
Galactose
Glucose
hCG
Ketones
Leucocytes
Nitrite
pH
Protein
Specific Gravity
Urobilinogen

Urine Toxicology Programme+

RQ9139 (5 ml)
20 Parameters
Samples every month, 1 x 12 month cycle, 12 month subscription

Benzoylecgonine
Buprenorphine
Cannabinoids (THC)
Cotinine
Creatinine
d-Amphetamine
d-Methamphetamine
EDDP
Ethanol
Free Morphine
Lorazepam
LSD
MDMA
Methadone
Nortriptyline
Norpropoxyphene
Oxazepam
Phencyclidine
Phenobarbital
Secobarbital

Whilst every attempt is made to ensure that information is accurate and up-to-date, some information is subject to change, please contact RIQAS for current details.

= Liquid ready-to-use samples = Lyophilised samples PURPLE = The only parameters available on RQ9135/a + = Not accredited * = Pilot study ongoing

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

		Ammonia / Ethanol	Anti-Mullerian Hormone (AMH) +	Anti-TSH Receptor +	Blood Gas	BNP +	Cardiac	Cardiac Plus	Cerebrospinal Fluid +	Coagulation	CO-Oximetry +	CYFRA 21-1 +	Cytokines +	ESR +	General Clinical Chemistry	HbA1c	Haematology	Human Urine	Immunoassay
#	1-25-$(OH)_2$-Vitamin D*																		X
	17-OH-Progesterone																		X
	25-OH-Vitamin D																		X
	5-HIAA																	X	
A	α-1-Acid Glycoprotein																		
	α-1-Antitryspin																		
	α-2-Macroglobulin																		
	ACE (Angiotensin Converting Enzyme)														X				
	Acid Phosphatase (Prostatic)														X				
	Acid Phosphatase (Total)														X				
	ACR																	X	
	ACTH																		X
	AFP																		X
	Albumin								X						X			X	
	Aldosterone																		X
	Alkaline Phosphatase														X				
	ALT																		
	ALT (ALAT)														X				
	Amikacin																		X
	Ammonia	X																	
	Amylase (Pancreatic)														X				
	Amylase (Total)														X			X	
	Androstenedione																		X
	Anti Streptolysin O (ASO)																		
	Anti-CMV																		
	Anti-CMV IgG																		
	Anti-CMV IgM																		
	Anti-EBNA IgG																		
	Anti-EBV VCA IgG																		
	Anti-EBV VCA IgM																		
	Anti-HAV IgM*																		
	Anti-HAV (Total)*																		
	Anti-HBc																		
	Anti-HBc IgM*																		
	Anti-HBe (Total)*																		
	Anti-HBs (Total)*																		
	Anti-HCV																		
	Anti-HIV-1																		
	Anti-HIV-1 & 2 Combined																		
	Anti-HIV-2																		
	Anti-HSV-1 & 2 IgG Combined																		
	Anti-HSV-1 & 2 IgM Combined																		
	Anti-HSV1 IgG																		
	Anti-HSV1 IgM																		
	Anti-HSV2 IgG																		
	Anti-HSV2 IgM																		
	Anti-HTLV-1 & 2 Combined																		
	Anti-HTLV-I																		
	Anti-HTLV-II																		
	Anti-Measles IgG*																		
	Antimicrobial Susceptibility Testing																		

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

Immunoassay Speciality 1	Immunoassay Speciality 2	Immunosuppressant +	Lipid	Maternal Screening	Microbiology (Bacterial Identification) +	Neonatal Bilirubin +	Serology (Anti-SARS-CoV-2) +	Serology (EBV) +	Serology (HIV / Hepatitis) +	Serology (Syphilis) +	Serology (ToRCH) +	Serum Indices +	Specific Proteins	Sweat Testing +	Therapeutic Drug	Urinalysis	Urine Toxicology +		
X																		1-25-$(OH)_2$-Vitamin D*	#
																		17-OH-Progesterone	
X																		25-OH-Vitamin D	
																		5-HIAA	
													X					α-1-Acid Glycoprotein	A
													X					α-1-Antitryspin	
													X					α-2-Macroglobulin	
																		ACE (Angiotensin Converting Enzyme)	
																		Acid Phosphatase (Prostatic)	
																		Acid Phosphatase (Total)	
																		ACR	
																		ACTH	
				X									X					AFP	
													X			X		Albumin	
																		Aldosterone	
												X						Alkaline Phosphatase	
												X						ALT	
																		ALT (ALAT)	
															X			Amikacin	
																		Ammonia	
																		Amylase (Pancreatic)	
																		Amylase (Total)	
																		Androstenedione	
													X					Anti Streptolysin O (ASO)	
									X									Anti-CMV	
											X							Anti-CMV IgG	
											X							Anti-CMV IgM	
								X										Anti-EBNA IgG	
								X										Anti-EBV VCA IgG	
								X										Anti-EBV VCA IgM	
									X									Anti-HAV IgM*	
									X									Anti-HAV (Total)*	
									X									Anti-HBc	
									X									Anti-HBc IgM*	
									X									Anti-HBe (Total)*	
									X									Anti-HBs (Total)*	
									X									Anti-HCV	
									X									Anti-HIV-1	
									X									Anti-HIV-1 & 2 Combined	
									X									Anti-HIV-2	
											X							Anti-HSV-1 & 2 IgG Combined	
											X							Anti-HSV-1 & 2 IgM Combined	
											X							Anti-HSV1 IgG	
											X							Anti-HSV1 IgM	
											X							Anti-HSV2 IgG	
											X							Anti-HSV2 IgM	
									X									Anti-HTLV-1 & 2 Combined	
									X									Anti-HTLV-I	
									X									Anti-HTLV-II	
											X							Anti-Measles IgG*	
					X													Antimicrobial Susceptibility Testing	

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

		Ammonia / Ethanol	Anti-Mullerian Hormone (AMH) +	Anti-TSH Receptor +	Blood Gas	BNP +	Cardiac	Cardiac Plus	Cerebrospinal Fluid +	Coagulation	CO-Oximetry +	CYFRA 21-1 +	Cytokines +	ESR +	General Clinical Chemistry	HbA1c	Haematology	Human Urine	Immunoassay
A	Anti-Müllerian Hormone (AMH)		X																
	Anti-Mumps IgG*																		
	Anti-Rubella IgG																		
	Anti-Rubella IgM																		
	Anti-SARS-COV2 IgG																		
	Anti-SARS-COV2 IgM																		
	Anti-SARS-COV2 Total																		
	Anti-TG																		
	Antithrombin III									X									
	Anti-Toxoplasma IgG																		
	Anti-Toxoplasma IgM																		
	Anti-TPO																		
	Anti-TSH Receptor (TRAb)			X															
	Anti-VZV IgG*																		
	Apolipoprotein AI																		
	Apolipoprotein B																		
	aPTT									X									
	AST																		
	AST (ASAT)														X				
B	β-2-Microglobulin																		X
	Benzoylecgonine																		
	Bicarbonate				X										X				
	Bile Acids														X				
	Bilirubin (Direct)														X				
	Bilirubin (Total)														X				
	Blood																		
	BNP					X													
	Buprenorphine																		
C	CA15-3																		X
	CA19-9																		X
	CA125																		X
	Caffeine																		
	Calcitonin																		
	Calcium														X			X	
	Calcium, Adjusted														X				
	Calcium (Ionised)				X										X				
	Cannabinoids (THC)																		
	Carbamazepine																		X
	Carboxyhaemoglobin (COHb / HbCO)										X								
	CEA																		X
	Ceruloplasmin																		
	Chloride				X				X						X			X	
	Cholesterol (Total)														X				
	Cholinesterase														X				
	Ciclosporin																		
	CK, Total						X	X							X				
	CK-MB (Activity)						X	X											
	CK-MB (Mass)						X	X											
	CK NAC																		
	CO2, Total				X														
	Complement C_3																		

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

Immunoassay Speciality 1	Immunoassay Speciality 2	Immunosuppressant +	Lipid	Maternal Screening	Microbiology (Bacterial Identification) +	Neonatal Bilirubin +	Serology (Anti-SARS-CoV-2) +	Serology (EBV) +	Serology (HIV / Hepatitis) +	Serology (Syphilis) +	Serology (ToRCH) +	Serum Indices +	Specific Proteins	Sweat Testing +	Therapeutic Drug	Urinalysis	Urine Toxicology +		
																		Anti-Müllerian Hormone (AMH)	A
											X							Anti-Mumps IgG*	
											X							Anti-Rubella IgG	
											X							Anti-Rubella IgM	
							X											Anti-SARS-COV2 IgG	
							X											Anti-SARS-COV2 IgM	
							X											Anti-SARS-COV2 Total	
X																		Anti-TG	
													X					Antithrombin III	
											X							Anti-Toxoplasma IgG	
											X							Anti-Toxoplasma IgM	
X																		Anti-TPO	
																		Anti-TSH Receptor (TRAb)	
											X							Anti-VZV IgG*	
			X															Apolipoprotein AI	
			X															Apolipoprotein B	
																		aPTT	
												X						AST	
																		AST (ASAT)	
													X					β-2-Microglobulin	B
																	X	Benzoylecgonine	
																		Bicarbonate	
																		Bile Acids	
						X						X						Bilirubin (Direct)	
						X						X				X		Bilirubin (Total)	
																X		Blood	
																		BNP	
																	X	Buprenorphine	
																		CA15-3	C
																		CA19-9	
																		CA125	
															X			Caffeine	
	X																	Calcitonin	
												X						Calcium	
																		Calcium, Adjusted	
																		Calcium (Ionised)	
																	X	Cannabinoids (THC)	
															X			Carbamazepine	
																		Carboxyhaemoglobin (COHb / HbCO)	
																		CEA	
													X					Ceruloplasmin	
												X		X				Chloride	
			X									X						Cholesterol (Total)	
																		Cholinesterase	
		X													X			Ciclosporin	
																		CK, Total	
																		CK-MB (Activity)	
																		CK-MB (Mass)	
												X						CK NAC	
																		CO2, Total	
													X					Complement C_3	

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

		Ammonia / Ethanol	Anti-Mullerian Hormone (AMH) +	Anti-TSH Receptor +	Blood Gas	BNP +	Cardiac	Cardiac Plus	Cerebrospinal Fluid +	Coagulation	CO-Oximetry +	CYFRA 21-1 +	Cytokines +	ESR +	General Clinical Chemistry	HbA1c	Haematology	Human Urine	Immunoassay
C	Complement C_4																		
	Conductivity																		
	Copper														X			X	
	Cortisol																	X	X
	Cotinine																		
	C-Peptide																		X
	C-Reactive Protein (CRP)																		
	Creatinine														X			X	
	CYFRA 21-1 (Cytokeratin 19)											X							
D	D-3-Hydroxybutyrate														X				
	d-Amphetamine																		
	D-Dimer* Δ							X		X									
	Deoxyhaemoglobin (HHb)										X								
	DHEA Unconjugated																		X
	DHEA-Sulphate																		X
	Digoxin							X											X
	d-Methamphetamine																		
	Dopamine																	X	
E	EDDP																		
	eGFR (estimated glomerular filtration rate)														X				
	Epidermal Growth Factor (EGF)*												X						
	Epinephrine																	X	
	ESR													X					
	Ethanol	X																	
	Ethosuximide																		
	Everolimus																		
F	Factor II									X									
	Factor IX									X									
	Factor V									X									
	Factor VII									X									
	Factor VIII									X									
	Factor X									X									
	Factor XI									X									
	Factor XII									X									
	Ferritin																		X
	Fibrinogen									X									
	Folate																		X
	Free Morphine																		
	free β-hCG																		
	Fructosamine														X				
	FSH																		X
G	γ-GT														X				
	Galactose																		
	Gastrin																		
	Gentamicin																		X
	Growth Hormone (GH)																		X
	GLDH														X				
	Glucose				X				X						X			X	
H	Haematocrit (HCT)																X		
	Haemoglobin (Hb)																X		
	Total Haemoglobin (tHb)										X					X			

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

Immunoassay Speciality 1	Immunoassay Speciality 2	Immunosuppressant +	Lipid	Maternal Screening	Microbiology (Bacterial Identification) +	Neonatal Bilirubin +	Serology (Anti-SARS-CoV-2) +	Serology (EBV) +	Serology (HIV / Hepatitis) +	Serology (Syphilis) +	Serology (ToRCH) +	Serum Indices +	Specific Proteins	Sweat Testing +	Therapeutic Drug	Urinalysis	Urine Toxicology +		
													X					Complement C_4	C
														X				Conductivity	
																		Copper	
																		Cortisol	
																	X	Cotinine	
X																		C-Peptide	
													X					C-Reactive Protein (CRP)	
												X				X	X	Creatinine	
																		CYFRA 21-1 (Cytokeratin 19)	
																		D-3-Hydroxybutyrate	D
																	X	d-Amphetamine	
																		D-Dimer* $^{\Delta}$	
																		Deoxyhaemoglobin (HHb)	
																		DHEA Unconjugated	
																		DHEA-Sulphate	
															X			Digoxin	
																	X	d-Methamphetamine	
																		Dopamine	
																	X	EDDP	E
																		eGFR (estimated glomerular filtration rate)	
																		Epidermal Growth Factor (EGF)*	
																		Epinephrine	
																		ESR	
																	X	Ethanol	
															X			Ethosuximide	
		X																Everolimus	
																		Factor II	F
																		Factor IX	
																		Factor V	
																		Factor VII	
																		Factor VIII	
																		Factor X	
																		Factor XI	
																		Factor XII	
													X					Ferritin	
																		Fibrinogen	
																		Folate	
																	X	Free Morphine	
				X														free β-hCG	
																		Fructosamine	
																		FSH	
												X						γ-GT	G
																X		Galactose	
	X																	Gastrin	
															X			Gentamicin	
																		Growth Hormone (GH)	
																		GLDH	
												X				X		Glucose	
																		Haematocrit (HCT)	H
																		Haemoglobin (Hb)	
																		Total Haemoglobin (tHb)	

$^{\Delta}$ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

		Ammonia / Ethanol	Anti-Mullerian Hormone (AMH) +	Anti-TSH Receptor +	Blood Gas	BNP +	Cardiac	Cardiac Plus	Cerebrospinal Fluid +	Coagulation	CO-Oximetry +	CYFRA 21-1 +	Cytokines +	ESR +	General Clinical Chemistry	HbA1c	Haematology	Human Urine	Immunoassay
H	Haemolysis																		
	Haptoglobin																		
	HbA1c															X			
	HBsAg																		
	HBDH														X				
	hCG																		X
	HDL-Cholesterol														X				
	Homocysteine						X	X											
	hsCRP							X											
I	Icteric																		
	IgA																		
	IgE																		X
	IGF-1																		
	IgG								X										
	IgM																		
	Inhibin A																		
	Insulin																		X
	Interferon gamma (INF-Y)*												X						
	Interleukin – 1 alpha (IL-1α)*												X						
	Interleukin – 1 beta (IL-1β)*												X						
	Interleukin – 10 (IL-10)*												X						
	Interleukin – 2 (IL-2)*												X						
	Interleukin – 4 (IL-4)*												X						
	Interleukin – 6 (IL-6)												X						
	Interleukin – 8 (IL-8)*												X						
	Iron														X				
K	Kappa Light Chain (Free)																		
	Kappa Light Chain (Total)																		
	Ketones																		
L	Lactate				X				X						X				
	Lambda Light Chain (Free)																		
	Lambda Light Chain (Total)																		
	LD (LDH)														X				
	LDL-Cholesterol														X				
	Leucocytes																		
	Lipase														X				
	Lipoprotein (a)																		
	Lithium														X				
	Lorazepam																		
	LSD																		
	Luteinising Hormone (LH)																		X
M	Magnesium														X			X	
	MDMA																		
	Mean Cell Haemoglobin (MCH)																X		
	Mean Cell Haemoglobin Concentration (MCHC)																X		
	Mean Cell Volume (MCV)																X		
	Mean Platelet Volume (MPV)																X		
	Metanephrine																	X	
	Methadone																		
	Methaemoglobin (MetHb)										X								
	Methotrexate																		

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

Immunoassay Speciality 1	Immunoassay Speciality 2	Immunosuppressant +	Lipid	Maternal Screening	Microbiology (Bacterial Identification) +	Neonatal Bilirubin +	Serology (Anti-SARS-CoV-2) +	Serology (EBV) +	Serology (HIV / Hepatitis) +	Serology (Syphilis) +	Serology (ToRCH) +	Serum Indices +	Specific Proteins	Sweat Testing +	Therapeutic Drug	Urinalysis	Urine Toxicology +		
												X						Haemolysis	H
													X					Haptoglobin	
																		HbA1c	
									X									HBsAg	
																		HBDH	
																X		hCG	
			X									X						HDL-Cholesterol	
																		Homocysteine	
																		hsCRP	
												X						Icteric	I
													X					IgA	
													X					IgE	
X																		IGF-1	
													X					IgG	
													X					IgM	
				X														Inhibin A	
X																		Insulin	
																		Interferon gamma (INF-Y)*	
																		Interleukin – 1 alpha (IL-1α)*	
																		Interleukin – 1 beta (IL-1β)*	
																		Interleukin – 10 (IL-10)*	
																		Interleukin – 2 (IL-2)*	
																		Interleukin – 4 (IL-4)*	
																		Interleukin – 6 (IL-6)	
																		Interleukin – 8 (IL-8)*	
												X						Iron	
													X					Kappa Light Chain (Free)	K
													X					Kappa Light Chain (Total)	
																X		Ketones	
												X						Lactate	L
													X					Lambda Light Chain (Free)	
													X					Lambda Light Chain (Total)	
												X						LD (LDH)	
			X															LDL-Cholesterol	
																X		Leucocytes	
												X						Lipase	
			X															Lipoprotein (a)	
															X			Lithium	
																	X	Lorazepam	
																	X	LSD	
																		Luteinising Hormone (LH)	
												X						Magnesium	M
																	X	MDMA	
																		Mean Cell Haemoglobin (MCH)	
																		Mean Cell Haemoglobin Concentration (MCHC)	
																		Mean Cell Volume (MCV)	
																		Mean Platelet Volume (MPV)	
																		Metanephrine	
																	X	Methadone	
																		Methaemoglobin (MetHb)	
															X			Methotrexate	

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

		Ammonia / Ethanol	Anti-Mullerian Hormone (AMH) +	Anti-TSH Receptor +	Blood Gas	BNP +	Cardiac	Cardiac Plus	Cerebrospinal Fluid +	Coagulation	CO-Oximetry +	CYFRA 21-1 +	Cytokines +	ESR +	General Clinical Chemistry	HbA1c	Haematology	Human Urine	Immunoassay
M	Monocyte Chemoattractant Protein -1 (MCP-1)*												X						
	Myoglobin						X	X											
N	NEFA														X				
	Nitrite																		
	Non-HDL Cholesterol														X				
	Norepinephrine																	X	
	Normetanephrine																	X	
	Norpropoxyphene																		
	Nortriptyline																		
	NTproBNP							X											
O	Oestradiol																		X
	Osmolality														X			X	
	Osteocalcin																		
	Oxalate																	X	
	Oxazepam																		
	Oxygen Content (O2CT)										X								
	Oxygen Saturation (sO2 / Vol O2)										X								
	Oxyhaemoglobin (O2Hb / HbO2)										X								
P	P24*																		
	PAPP-A																		
	Paracetamol (Acetaminophen)																		X
	pCO_2				X														
	pH				X														
	Phencyclidine																		
	Phenobarbital																		X
	Phenytoin																		X
	Phosphate (Inorganic)														X			X	
	Plasma Renin Activity																		
	Plasminogen									X									
	Plateletcrit (PCT)																X		
	Platelets (PLT)																X		
	pO_2				X														
	Potassium				X										X			X	
	Prealbumin (Transthyretin)																		
	Primidone																		
	Procalcitonin																		
	Progesterone																		X
	Prolactin																		X
	Protein (Total)								X						X			X	
	Protein C									X									
	Protein S									X									
	PSA (Free)																		X
	PSA (Total)														X				X
	PT (Including INR)									X									
	PTH																		X
R	Red Blood Bell Count (RBC)																X		
	Red Cell Distribution Width (RDW)																X		
	Renin (Direct Concentration)																		
	Retinol Binding Protein																		
	Rheumatoid Factor																		
S	Salicylic Acid																		X

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

Immunoassay Speciality 1	Immunoassay Speciality 2	Immunosuppressant +	Lipid	Maternal Screening	Microbiology (Bacterial Identification) +	Neonatal Bilirubin +	Serology (Anti-SARS-CoV-2) +	Serology (EBV) +	Serology (HIV / Hepatitis) +	Serology (Syphilis) +	Serology (ToRCH) +	Serum Indices +	Specific Proteins	Sweat Testing +	Therapeutic Drug	Urinalysis	Urine Toxicology +		
																		Monocyte Chemoattractant Protein -1 (MCP-1)*	M
																		Myoglobin	
																		NEFA	N
																X		Nitrite	
																		Non-HDL Cholesterol	
																		Norepinephrine	
																		Normetanephrine	
																	X	Norpropoxyphene	
																	X	Nortriptyline	
																		NTproBNP	
																		Oestradiol	O
																		Osmolality	
X																		Osteocalcin	
																		Oxalate	
																	X	Oxazepam	
																		Oxygen Content (O2CT)	
																		Oxygen Saturation (sO2 / Vol O2)	
																		Oxyhaemoglobin (O2Hb / HbO2)	
									X									P24*	P
				X														PAPP-A	
															X			Paracetamol (Acetaminophen)	
																		pCO_2	
																X		pH	
																	X	Phencyclidine	
															X		X	Phenobarbital	
															X			Phenytoin	
												X						Phosphate (Inorganic)	
	X																	Plasma Renin Activity	
																		Plasminogen	
																		Plateletcrit (PCT)	
																		Platelets (PLT)	
																		pO_2	
																		Potassium	
													X					Prealbumin (Transthyretin)	
															X			Primidone	
X	X																	Procalcitonin	
																		Progesterone	
																		Prolactin	
												X				X		Protein (Total)	
																		Protein C	
																		Protein S	
																		PSA (Free)	
																		PSA (Total)	
																		PT (Including INR)	
X																		PTH	
																		Red Blood Bell Count (RBC)	R
																		Red Cell Distribution Width (RDW)	
	X																	Renin (Direct Concentration)	
													X					Retinol Binding Protein	
													X					Rheumatoid Factor	
															X			Salicylic Acid	S

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

		Ammonia / Ethanol	Anti-Mullerian Hormone (AMH) +	Anti-TSH Receptor +	Blood Gas	BNP +	Cardiac	Cardiac Plus	Cerebrospinal Fluid +	Coagulation	CO-Oximetry +	CYFRA 21-1 +	Cytokines +	ESR +	General Clinical Chemistry	HbA1c	Haematology	Human Urine	Immunoassay
S	Secobarbital																		
	SHBG																		X
	Sirolimus																		
	Sodium				X				X						X			X	
	Specific Gravity																		
	Strain Identification																		
	Syphilis																		
T	T_3 (Free)														X				X
	T_3 (Total)														X				X
	T_4 (Free)														X				X
	T_4 (Total)														X				X
	Tacrolimus																		
	Testosterone (Free)*																		X
	Testosterone (Total)																		X
	Theophylline																		X
	Thyroglobulin																		X
	TIBC														X				
	Tobramycin																		
	Total hCG																		
	Transferrin																		
	Triglycerides														X				
	Troponin I						X	X											
	Troponin T						X	X											
	TSH														X				X
	TT									X									
	Tumour Necrosis Factor alpha (TNF-α)*												X						
U	UIBC														X				
	Unconjugated Oestriol																		
	Urea														X			X	
	Uric Acid														X			X	
	Urobilinogen																		
V	Valproic Acid																		X
	Vancomycin																		X
	Vascular Endothelial Growth Factor (VEGF)*												X						
	Vitamin B12																		X
	VMA																	X	
W	Total White Blood Cell Count (WBC)																X		
Z	Zinc														X				

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

PARAMETER INDEX

+ = Not accredited

* = Pilot study ongoing

PURPLE = The only parameters available on RQ9135/a

Immunoassay Speciality 1	Immunoassay Speciality 2	Immunosuppressant +	Lipid	Maternal Screening	Microbiology (Bacterial Identification) +	Neonatal Bilirubin +	Serology (Anti-SARS-CoV-2) +	Serology (EBV) +	Serology (HIV / Hepatitis) +	Serology (Syphilis) +	Serology (ToRCH) +	Serum Indices +	Specific Proteins	Sweat Testing +	Therapeutic Drug	Urinalysis	Urine Toxicology +		
																	X	Secobarbital	S
																		SHBG	
		X																Sirolimus	
												X						Sodium	
																X		Specific Gravity	
					X													Strain Identification	
										X								Syphilis	
																		T_3 (Free)	T
																		T_3 (Total)	
																		T_4 (Free)	
																		T_4 (Total)	
		X																Tacrolimus	
																		Testosterone (Free)*	
																		Testosterone (Total)	
															X			Theophylline	
																		Thyroglobulin	
																		TIBC	
															X			Tobramycin	
				X														Total hCG	
													X					Transferrin	
			X									X						Triglycerides	
																		Troponin I	
																		Troponin T	
																		TSH	
																		TT	
																		Tumour Necrosis Factor alpha (TNF-α)*	
																		UIBC	U
				X														Unconjugated Oestriol	
												X						Urea	
												X						Uric Acid	
																X		Urobilinogen	
															X			Valproic Acid	V
															X			Vancomycin	
																		Vascular Endothelial Growth Factor (VEGF)*	
																		Vitamin B12	
																		VMA	
																		Total White Blood Cell Count (WBC)	W
																		Zinc	Z

Δ Pilot status only in certain programmes. Please check pages 42-46 for more information.

RANDOX QC PORTFOLIO

Our expertise in Quality Control have led to us creating market leading products that are tried and trusted by laboratory professionals. Our product portfolio offers high quality diagnostic solutions which offer reliable and rapid diagnosis and we believe that by providing laboratories with these tools, we can improve health worldwide.

ACUSERA - True third party controls offering complete test menu consolidation

Uniquely combining more than 100 analytes conveniently in a single control, laboratories can significantly reduce costs and consolidate without compromising on quality. As true third party controls, unbiased performance assessment with any instrument or method is guaranteed.

ACUSERA 24•7 - Online QC software with real-time peer group statistics

Designed for use with the Acusera range of third party controls, the Acusera 24•7 software will help you monitor and interpret your QC data. Access to an impressive range of features, including interactive charts, the automatic calculation of Measurement Uncertainty & Sigma Metrics and live peer group data generated from our extensive database of laboratory participants, ensures Acusera 24•7 is the most comprehensive package available.

ACUSERA VERIFY - Keep your instrument in check with calibration verification materials

Designed to challenge a larger section of an instruments reportable range and test if a system's calibration is still valid. Our linearity materials cover a wide range of testing including, CRP, RF, Lipids, Therapeutic Drugs, Esoterics and more. Designed with user convenience in mind, all our linearity sets are supplied in a liquid format and in varying levels. Our unique combination of analytes enables laboratories to reduce the number of individual products required while ultimately reducing costs and time.

MOLECULAR - IQC & EQA solutions for infectious disease testing

Our complete quality control solutions for molecular infectious disease testing comprise hundreds of characterised viral, bacterial and fungal targets. Covering a wide range of transplant associated diseases, respiratory infections, blood borne viruses, sexually transmitted infections and more, our Molecular IQC and EQA range covers the full laboratory portfolio. Both our product offering are manufactured using only the highest quality material and the availability of whole pathogen samples ensures the performance of the patient sample is mimicked throughout.

CONTACT US

Contact us for more information on any of our products and services:

HEADQUARTERS

Randox Laboratories Ltd, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom

☎ +44 (0) 28 9445 4399 ✉ marketing@randox.com randox.com

INTERNATIONAL OFFICES

AUSTRALIA
Randox (Australia) Pty Ltd.
Tel: +61 (0) 2 9615 4640

BRAZIL
Randox Brasil Ltda.
Tel: +55 11 5181-2024

CHINA
Randox Laboratories Ltd.
Tel: +86 021 6288 6240

CZECH REPUBLIC
Randox Laboratories S.R.O.
Tel: +420 2 1115 1661

FRANCE
Laboratoires Randox
Tel: +33 (0) 130 18 96 80

GERMANY
Randox Laboratories GmbH
Tel: +49 (0) 215 1937 0611

HONG KONG
Randox Laboratories Hong Kong Limited
Tel: +852 3595 0515

ITALY
Randox Laboratories Ltd.
Tel: +39 06 9896 8954

INDIA
Randox Laboratories India Pvt Ltd.
Tel: +91 80 2802 5000

POLAND
Randox Laboratories Polska Sp. z o.o.
Tel: +48 22 862 1080

PORTUGAL
Irlandox Laboratorios Quimica Analitica Ltda
Tel: +351 22 589 8320

PUERTO RICO
Clinical Diagnostics of Puerto Rico, LLC
Tel: +1 787 701 7000

REPUBLIC OF IRELAND
Randox Teoranta
Tel: +353 7495 22600

SLOVAKIA
Randox S.R.O.
Tel: +421 2 6381 3324

SOUTH AFRICA
Randox Laboratories SA (Pty) Ltd.
Tel: +27 (0) 11 312 3590

SOUTH KOREA
Randox Korea
Tel: +82 (0) 31 478 3121

SPAIN
Laboratorios Randox S.L.
Tel: +34 93 475 09 64

SWITZERLAND
Randox Laboratories Ltd. (Switzerland)
Tel: +41 41 810 48 89

UAE
Randox Medical Equipments Trading LLC
Tel: +971 55 474 9075

USA
Randox Laboratories-US, Ltd.
Tel: +1 304 728 2890

VIETNAM
Randox Laboratories Ltd. Vietnam
Tel: +84 (0) 8 3911 0904

For technical support contact: mail@riqas.com

Whilst every attempt is made to ensure that information is accurate and up-to-date, some information is subject to change.
Please contact **marketing@randox.com** for current details.

RIQAS

UKAS PROFICIENCY TESTING 0010

LT033 FEB24

RANDOX

ПРОГРАММЫ ВНЕШНЕЙ ОЦЕНКИ КАЧЕСТВА

МЕЖДУНАРОДНАЯ СИСТЕМА ВНЕШНЕЙ ОЦЕНКИ КАЧЕСТВА RANDOX

ХАРАКТЕРИСТИКИ И ПРЕИМУЩЕСТВА

Международная система внешней оценки качества Randox RIQAS

RIQAS – крупнешшая международная система внешней оценки качества (ВОК), используемая в более чем 55000 лабораториях участницах в более чем 134 странах. Такое большое количество участников обеспечивает обширную базу данных результатов для многочисленных аналитических методов, что напрямую повышает статистическую достоверность.

Преимущества

Большая база данных результатов, полученных участниками

- Высокий уровень участия означает, что размер групп сравнения максимально увеличивается, обеспечивая, таким образом, наличие достаточного объема данных по широкому спектру приборов и методов.

Простые и удобные отчеты

- Простой одностраничный формат отчёта по каждому аналиту позволяет оценивать результаты с одного взгляда, экономя ценное время лаборатории.
- Дополнительные отчеты по группе приборов / лабораторий позволяют проводить сравнительную оценку всех аналитических систем и лабораторий, входящих в группу.
- Итоговые отчеты по окончанию цикла суммируют результаты оценки за текущий цикл в сравнении с результатами предыдущего цикла, позволяя выявлять изменения в уровне качества за продолжительные периоды времени.

Экономическая эффективность

- Широкий спектр программ, включающих большой перечень аналитов позволяет сократить число отдельных программ, требуемых для охвата всего Вашего меню тестов, экономя время и средства лаборатории.
- Наличие для ряда программ вариантов с сокращенным перечнем аналитов обеспечивает большую гибкость и соответствие требованиям лабораторий разного размера и бюджета.
- Возможность регистрации до пяти приборов на одну программу без дополнительной платы для проведения их индивидуальной и сравнительной оценки.

Частота исследований

- Частое проведение ВОК позволяет оперативнее выявлять ошибки в работе тест-систем и проводить корректирующие действия, минимизируя последствия для лаборатории.
- Короткий цикл обработки результатов - менее, чем 72 часа для большинства отчетов позволяет раньше выполнить необходимые корректирующие действия, что потенциально снижает количество повторных анализов образцов пациентов в случае выявления ошибок в КК.

Высокое качество образцов

- Образцы, охватывающие все клинически значимые уровни аналитов позволяют выявлять сдвиги в концентрациях, помогая
- Образцы человеческого происхождения не содержат добавок и консервантов, влияющих на результаты измерения, увеличивают уверенность в том, что результаты ВОК адекватно отражают уровень правильности результатов для образцов пациентов.
- Для ряда аналитов и партий контрольных образцов программы по клинической химии предоставляются значения, полученные референсными методами.



Высокая авторитетность

- Программы RIQAS признаны национальными и международными органами аккредитации по всему миру.
- Сертификаты RIQAS свидетельствуют об участии в авторитетной системе ВОК.

ПРОГРАММЫ RIQAS

Программа Аммиак/Этанол+ (Ammonia/Ethanol Program+) *С оценкой по цели*

RQ9164 (2 мл)
2 Аналита
Ежемесячная, годовое участие

Аммиак	Этанол

Программа Антитела к рецептору ТТГ+ (Anti-TSH Receptor Program+) *С оценкой по цели*

RQ9174 (1 мл)
1 Аналит
Ежемесячная, годовое участие

Антитела к рецептору ТТГ (TRAb)

Программа Газы крови (Blood Gas Program) *С оценкой по цели*

RQ9134 (1.8 мл)
First registered instrument
11 аналитов
Ежемесячная, годовое участие

RQ9134/A (1.8 мл)
Subsequent instruments
11 аналитов

Бикарбонаты	CO2(Общий)	K+	pH
Ca++	Глюкоза	Na+	pO2
Cl-	Лактат	pCO2	

Программа Мозговой натрийуретический пептид+ (BNP Program+) *С оценкой по цели*

RQ9165 (1 мл)
1 Аналит
Ежемесячная, годовое участие

Мозговой натрийуретический пептид (BNP)

Кардиологическая Программа (Cardiac Program) *С оценкой по цели*

RQ9127/a (1 мл)
2 Аналита (сна выбор из 7)
Образцы раз в 2 недели, 2 полугодовых цикла, годовое участие

RQ9127/b (1 мл)
Все 7 аналитов

RQ9186 (1 мл)
Все 7 аналитов
Ежемесячная, годовое участие

Креатинкиназа Общая	КК-МВ (Масса)	Миоглобин	Тропонин Т
КК-МВ (Активность)	Гомоцистеин	Тропонин I	

Кардиологическая Расширенная Программа (Cardiac Plus Program) *С оценкой по цели*

RQ9190 (3 мл)
11 аналитов
Ежемесячная, годовое участие

Креатинкиназа Общая	Д-Димер	СРБ высокочувствительный	Тропонин I
КК-МВ (Активность)	Дигоксин	Миоглобин	Тропонин Т
КК-МВ (Масса)	Гомоцистеин	NT proBNP	

Программа Спиномозговая жидкость+ (Cerebrospinal Fluid Program+) *С оценкой по цели*

RQ9168 (3 мл)
7 аналитов
Ежемесячная, годовое участие

Альбумин	Глюкоза	Лактат	Натрий
Хлориды	IgG	Белок (Общий)	

– Жидкие, готовые к использованию – Лиофилизированные ФИОЛЕТОВЫЙ = Доступны только в программе RQ9135/a + = Не аккредитованы * = Пилотный цикл

ПРОГРАММЫ RIQAS

Программа Коагуляция (Coagulation Program) *С оценкой по цели*

RQ9135/a (1 мл) 5 аналитов + 1 пилотный аналит (АЧТВ, ПТВ, ТВ, Фибриноген, Антитромбин III) Ежемесячная, годовое участие	RQ9135/b (1 мл) Все 16 аналитов + 1 пилотный аналит		
АЧТВ Протромбиновое время (Включая МНО) Тромбиновое время Фибриноген Антитромбин III	Д-Димер* Фактор II Фактор V Фактор VII Фактор VIII	Фактор IX Фактор X Фактор XI Фактор XII Плазминоген	Протеин C Протеин S

Программа CO-оксиметрия+ (CO-Oximetry Program+)

RQ9177 (1.2 мл) Первый анализатор 7 аналитов Ежемесячная, годовое участие	RQ9177/A (1.2 мл) Дополнительные анализаторы 7 аналитов		
Карбоксигемоглобин (COHb / HbCO) Дезоксигемоглобин (HHb)	Метгемоглобин (MetHb) Содержание кислорода(O2CT)	Сатурация кислородом (sO2 / Vol O2) Оксигемоглобин (O2Hb / HbO2)	Общий гемоглобин (tHb)

Программа Онкомаркер CYFRA 21-1+ (CYFRA 21-1 Program+)

RQ9175 (1 мл) 1 Аналит Ежемесячная, годовое участие
CYFRA 21-1 (Цитокератин 19)

Программа Цитокины+ (Cytokines Program+)

RQ9195 (1 мл) 1 Аналит + 11 pilots Ежемесячная, годовое участие			
Эпидермальный фактор роста (EGF)* Интерлейкин – 1 альфа (IL-1α)* Интерлейкин – 1 бета (IL-1β)* Интерлейкин – 2 (IL-2)*	Интерлейкин – 4 (IL-4)* Интерлейкин – 6 (IL-6) Интерлейкин – 8 (IL-8)* Интерлейкин – 10 (IL-10)*	Интерферон гамма (INF-Y)* Белок-хемоаттрактант моноцитов -1 (MCP-1)* Фактор некроза опухоли альфа (TNF-α)*	Сосудистый эндотелиальный фактор роста (VEGF)*

Программа СОЭ+ (ESR Programme+)

RQ9163 (4.5 мл) 1 Аналит 2 образца в квартал, годовое участие
СОЭ (Скорость оседания эритроцитов)

Программа Общая клиническая химия (General Clinical Chemistry Program) *С оценкой по цели*

RQ9112/a (5 мл) 10 аналитов + 4 пилотных	RQ9112/b (5 мл) 17 аналитов + 4 пилотных	RQ9112/c (5 мл) Все 52 Аналита + 4 пилотных	RQ9128 (5мл) Все 52 Аналита + 4 пилотных
Образцы раз в 2 недели, 2 полугодовых цикла, годовое участие, данные по референсным методам			Ежемесячная, годовое участие
АПФ (ангиотензинпревращающий фермент) Кислая фосфатаза (Простатическая) Кислая фосфатаза (Общая) Альбумин Щелочная фосфатаза АЛТ (АЛАТ) Амилаза (Панкреатическая) Амилаза (Общая) АСТ (АСАТ) Бикарбонаты Желчные кислоты Билирубин (Прямой) Билирубин (Общий) Кальций Кальций, скорректированный*	Кальций (Ионизированный) Хлориды Холестерин Холинэстераза Креатинкиназа (Общая) Медь Креатинин D-3-Гидроксибутират рСКФ (расчетная скорость клубочковой фильтрации)* Фруктозамин ГГТ GLDH Глюкоза Гидроксибутиратдегидрогеназа	Холестерин ЛПВП Железо Лактат Лактатдегидрогеназа (LDH) Холестерин ЛПНП* Липаза Литий Магний Неэтерифицированные жирные кислоты (НЭЖК) Холестертин не ЛПВП* Осмоляльность Фосфор (Неорганический) Калий Белок (Общий)	ПСА Натрий ОЖСС Т3 (Свободный) Т3 (Общий) Т4 (Свободный) Т4 (Общий) Триглицериды ТТГ НЖСС Мочевина Мочевая кислота Цинк

– Жидкие, готовые к использованию – Лиофилизированные ФИОЛЕТОВЫЙ – Доступны только в программе RQ9135/a + = Не аккредитованы * = Пилотный цикл

ПРОГРАММЫ RIQAS

Программа Гликозилированный гемоглобин (Glycated Haemoglobin Program (HbA1c)

С оценкой по цели

RQ9129 (0.5мл)
2 Аналита
Ежемесячная, годовое участие

Гемоглобин A1c

Общий гемоглобин

Программа Гематология (Haematology Program) *С оценкой по цели*

RQ9118 (2 мл)
11 аналитов
Образцы раз в 2 недели, 2 полугодовых цикла, годовое участие

RQ9140 (2мл)
11 аналитов
Ежемесячная, годовое участие

Гематокрит (HCT)
Гемоглобин (Hb)
Среднее содержание гемоглобина в эритроците (MCH)
Средняя концентрация гемоглобина в эритроците (MCHC)
Средний объём эритроцита (MCV)
Средний объём тромбоцита (MPV)
Тромбоциты (PLT)
Тромбокрит (PCT)
Эритроциты (RBC)
Ширина распределения эритроцитов (RDW)
Лейкоциты (WBC)

Программа Биохимия мочи (Human Urine Program) *С оценкой по цели*

RQ9115 (10 мл)
25 аналитованалитовОбразцы раз в 2 недели, 2 полугодовых цикла, годовое участие

RQ9185 (10мл)
25 Аналита
Ежемемсячная, годовое участие

ACR
Альбумин (Микроальбумин)
Амилаза
Кальций
Хлор
Медь
Кортизол
Креатинин
Дофамин
Эпинефрин
Глюкоза
Метанефрин
Норэпинефрин
Норметанефрин
Магний
Осмоляльность
Оксалат
Фосфор (Неорганический)
Калий
Белок (Общий)
Натрий
Мочевина
Мочевая кислота
Ванилилминдальная кислота (VMA)
5-гидроксииндолилуксусная кислота (5-HIAA)

Программа Иммунохимия (Immunoassay Program) *С оценкой по цели*

RQ9125/a (5 мл)
4 Аналита + 2 пилотных

RQ9125/b (5 мл)
13 Аналита + 2 пилотных

RQ9125/c (5 мл)
Все 49 Аналита + 2 пилотных

RQ9130 (5 мл)
Все 49 Аналита + 2 пилотных
Ежемесячная, годовое участие RQ9130)

Образцы раз в 2 недели, 2 полугодовых цикла, годовое участие (RQ9125/a, RQ9125/b, RQ9125/c)

АКТГ
Альфа-фетопротеин (АФП)
Альдостерон
Амикацин
Андростендион
β-2-Микроглобулин
CA125
CA15-3
CA19-9
Карбамазепин
РЭА
Кортизол
С-пептид
ДГЭА-сульфат
ДГЭА неконъюгированный
Дигоксин
Ферритин
Фолат
ФСГ
Гентамицин
Гормон роста
ХГЧ
IgE
Инсулин
Лютеонизирующий гормон
Эстрадиол
17-ОН-Прогестерон
Парацетамол
Фенобарбитал
Фенитоин
Прогестерон
Пролактин
ПСА (Свободный)
ПСА (Общий)
Паратериоидный гормон (ПТГ)
Салицилаты
ГСПГ
Т3 (Свободный)
Т3 (Общий)
Т4 (Свободный)
Т4 (Общий)
Testosterone (Свободный)*
Testosterone (Общий)
Теофилин
Тиреоглобулин
ТТГ
Вальпроевая кислота
Ванкомицин
Витамин B12
1,25-(OH)2-Витамин D*
25-OH-Витамин D

Программа Специальная иммунохимия 1 (Immunoassay Specialty 1 Program)

С оценкой по цели

RQ9141 (2 мл)
9 аналитов + 1 пилотный
Ежемесячная, годовое участие

1,25-(OH)2-Витамин D*
25-OH-Витамин D
С-пептид
Анти-Тиреоглобулин
Анти-Тиреопероксидаза
Инсулиноподобный фактор роста-1
Остеокальцин
Прокальцитонин
Паратиреоидный гормон
Инсулин

Программа Специальная иммунохимия 2 (Immunoassay Specialty 2 Program)

С оценкой по цели

RQ9142 (1 мл)
5 аналитов
Ежемесячная, годовое участие

Кальцитонин
Гастрин
Прокальцитонин
Ренин (Активность в плазме)
Ренин (Прямое определение концентрации)

= Жидкие, готовые к использованию = Лиофилизированные ФИОЛЕТОВЫЙ = Доступны только в программе RQ9135/a + = Не аккредитованы * = Пилотный цикл

ПРОГРАММЫ RIQAS

Программа Иммунодепрессанты+ (Immunosuppressant Program+)

RQ9159 (2 мл)
4 Аналита
Ежемесячная, годовое участие, данные референсных методов

Циклоспорин	Эверолимус	Сиролимус	Такролимус

Программа Липиды (Lipid Program) *С оценкой по цели*

RQ9126/a (3 мл)
3 Аналита (на выбор из 7)
RQ9126/b (3 мл)
Все 7 Аналита
Образцы раз в 2 недели, 2 полугодовых цикла, годовое участие

Аполипопротеин A1 Аполипопротеин B	Холестерин (Общий) Холестерин ЛПВП	Холестерин ЛПНП Липопротеин (a)	Триглицериды

Программа Перинатальный скрининг (Maternal Screening Program) *С оценкой по цели*

RQ9137 (1 мл)
6 аналитов
Ежемесячная, годовое участие

Альфа-фетопротеин Свободный β-ХГЧ	ХГЧ (Общий) Ингибин А	PAPP-A	Эстриол неконьюгированный

Программа Неонатальный билирубин+ (Neonatal Bilirubin Program+)

RQ9191 (3 мл)
2 Аналита
Ежемесячная, годовое участие

Билирубин Прямой	Билирубин Общий

Программа Серология Анти-SARS-CoV-2+ (Serology (Anti-SARS-CoV-2) Program+)

RQ9193 (0.5 мл)
3 Аналита
Ежемесячная, годовое участие

IgG	IgM	Суммарные антитела

Программа Серология Вирус Эпштейна–Барр+ (Serology (EBV) Program+)

RQ9153 (1 мл)
3 Аналита
Ежемесячная, годовое участие, количественный и качественные результаты

Anti-EBV VCA IgG	Anti-EBNA IgG	Anti-EBV VCA IgM

Программа Серология ВИЧ+ (Serology (HIV-Hepatitis) Program+)

RQ9151 (1.8 мл)
16 аналитов
Ежемесячная, годовое участие, количественный и качественные результаты

Антитела к цитомегаловирусу (Суммарные) Антитела к вирусу гепатита A IgM* Антитела к вирусу гепатита A (Суммарные)* Антитела к ядерному антигену вируса гепатита B (Суммарные)	Антитела к ядерному антигену вируса гепатита B IgM* Антитела к e-антигену вируса гепатита B (Суммарные)* Антитела к поверхностному антигену вируса гепатита B (Суммарные)* Антитела к вирусу гепатита C Антитела к ВИЧ-1	Антитела к ВИЧ-2 Антитела к ВИЧ (Комбинированные) Антитела к Т-лимфотропному вирусу человека I Антитела к Т-лимфотропному вирусу человека II Антитела к Т-лимфотропному вирусу человека (Комбинированные)	Поверхностный антиген вируса гепатита B (HBsAg) Антиген ВИЧ P24*

= Жидкие, готовые к использованию = Лиофилизированные ФИОЛЕТОВЫЙ = Доступны только в программе RQ9135/a + = Не аккредитованы * = Пилотный цикл

Программа Серология Сифилис+ (Serology (Syphilis) Program+)

RQ9154 (1 мл)
1 Аналит
Ежемесячная, годовое участие, количественный и качественные результаты

Сифилис (Доступные методы включают: иммунохимический анализ, RPR, VDRL и TPHA)

Программа Серология ToRCH+ (Serology (ToRCH) Program+)

RQ9152 (1 мл)
15 аналитов
Ежемесячная, годовое участие, количественный и качественные результаты

- Антитела к цитомегаловирусу IgG
- Антитела к цитомегаловирусу IgM
- Антитела к вирусу простого герпеса 1 IgG
- Антитела к вирусу простого герпеса 1 IgM
- Антитела к вирусу простого герпеса 2 IgG
- Антитела к вирусу простого герпеса 2 IgM
- Антитела к вирусу простого герпеса 1/2 IgG
- Антитела к вирусу простого герпеса 1/2 IgM
- Антитела к вирусу кори IgG*
- Антитела к вирусу свинки IgG*
- Антитела к вирусу краснухи IgG
- Антитела к вирусу краснухи IgM
- Антитела к вирусу токсоплазмы IgG
- Антитела к вирусу токсоплазмы IgM
- Антитела к вирусу ветряной оспы IgG*

Программа Сывороточные индексы+ (Serum Indices Program+)

RQ9194 (1 мл)
Оценка 3 индексов
25 аналитов
Образцы дважды в месяц (9 образцов в поставке), 2 поставки за цикл

RQ9194/A (1 мл)

Оценка индексов (Качественно и полу-количественно)

- Гемолиз
- Иктеричность
- Липемичность

Определяемые аналиты (Количественно)

- Щелочная фосфатаза
- АЛТ (АЛАТ)
- АСТ (АСАТ)
- Билирубин (Прямой)
- Билирубин (Общий)
- Кальций
- Хлориды
- Холестерин
- NAC-активированная креатинкиназа
- Креатинин
- ГГТ
- Глюкоза
- Холестерин ЛПВП
- Железо
- Лактат
- Холестерин ЛПНП
- Липаза
- Магний
- Фосфор
- Калий
- Белок (Общий)
- Натрий
- Триглицериды
- Мочевина
- Мочевая кислота

Программа Специфические белки (Specific Proteins Program) *С оценкой по цели*

RQ9114 (3 мл)
26 аналитов
Образцы раз в 2 недели, 2 полугодовых цикла, годовое участие

RQ9187 (1мл)
26 аналитов
Ежемесячная, годовое участие

- Альфа-фетопротеин
- Альбумин
- α-1-кислый гликопротеин
- α-1-антитрипсин
- α-2-макроглобулин
- Анти-стрептолизин О
- Антитромбин III
- β-2-микроглобулин
- Церулоплазмин
- Комплемент C3
- Комплемент C4
- С-реактивный белок
- Ферритин
- Гаптоглобин
- IgA
- IgE
- IgG
- IgM
- Каппа легкая цепь (Свободная)
- Каппа лёгкая цепь (Общая)
- Лямбда лёгкая цепь (Свободная)
- Лямбда лёгкая цепь (Общая)
- Преальбумин (Транстиретин)
- Ретинол-связывающий белок
- Ревматоидный фактор
- Трансферрин

Программа Исследование пота+ (Sweat Testing Program+)

RQ9173 (2 мл)
2 аналитов
Ежемесячная, годовое участие

- Хлориды
- Электропроводность

Программа Лекарственный мониторинг (Therapeutic Drugs Program) *С оценкой по цели*

RQ9111 (5 мл)
18 аналитов
Образцы раз в 2 недели, 2 полугодовых цикла, годовое участие, Взвешенные значения

- Амикацин
- Кофеин
- Карбамазепин
- Циклоспорин
- Дигоксин
- Этосуксимид
- Гентамицин
- Литий
- Метотрексат
- Парацетамол (ацетаминофен)
- Фенобарбитал
- Фенитоин
- Примидон
- Салициловая кислота
- Теофиллин
- Тобрамицин
- Вальпроевая кислота
- Ванкомицин

= Жидкие, готовые к использованию = Лиофилизированные ФИОЛЕТОВЫЙ = Доступны только в программе RQ9135/a + = Не аккредитованы * = Пилотный цикл

ПРОГРАММЫ RIQAS

Программа Микроэлементы в цельной крови+ (Trace Elements In Blood Program+)

RQ9172 (3 мл)
7 аналитов
Ежемесячная, годовое участие

Медь	Свинец	Марганец	Цинк
Йод	Магний	Селен	

Программа Микроэлементы в сыворотке+ (Trace Elements In Serum Program+)

RQ9170 (3 мл)
10 аналитов
Ежемесячная, годовое участие

Алюминий	Медь	Марганец	Цинк
Хром	Йод	Никель	
Кобальт	Свинец	Селен	

Программа Микроэлементы в моче+ (Trace Elements In Urine Program+)

RQ9171 (3 мл)
11 аналитов
Ежемесячная, годовое участие

Кадмий	Медь	Магний	Никель
Хром	Йод	Марганец	Таллий
Кобальт	Свинец	Молибден	

Программа Общий анализ мочи (Urinalysis Program) *With scoring*

RQ9138 (12 мл)
14 аналитов
Образцы каждые 2 месяца, годовое участие

Альбумин	Галактоза	Лейкоциты	Удельный вес
Билирубин	Глюкоза	Нитриты	Уробилиноген
Кровь	ХГЧ	pH	
Креатинин	Кетоны	Белок (Общий)	

Программа Токсикология мочи+ (Urine Toxicology Program+)

RQ9139 (5 мл)
20 аналитов
Ежемесячная, годовое участие

Бензолекгонин	d-метамфетамин	ЛСД	Фенциклидин
Бупренорфин	2-Этилиден-1,5-диметил-3,3-дифенилпирролидин (EDDP)	МДМА	Фенобарбитал
Каннабиноиды (ТГК)		Метадон	Секобарбитал
Котинин	Этанол	Нортриптилин	
Креатинин	Свободный морфин	Норпропоксифен	
d-амфетамин	Лоразепам	Оксазепам	

= Жидкие, готовые к использованию = Лиофилизированные ФИОЛЕТОВЫЙ = Доступны только в программе RQ9135/a + = Не аккредитованы * = Пилотный цикл

Несмотря на то, что предпринимаются все усилия, чтобы обеспечить точность и актуальность информации в наших каталогах, некоторые данные могут быть изменены, пожалуйста, свяжитесь с RIQAS для получения актуальной информации.

RIQAS

UKAS PROFICIENCY TESTING 0010

LT208RUS APR22